US20020051812A1 - Drug delivery via therapeutic hydrogels - Google Patents

Drug delivery via therapeutic hydrogels Download PDF

Info

Publication number
US20020051812A1
US20020051812A1 US09/849,481 US84948101A US2002051812A1 US 20020051812 A1 US20020051812 A1 US 20020051812A1 US 84948101 A US84948101 A US 84948101A US 2002051812 A1 US2002051812 A1 US 2002051812A1
Authority
US
United States
Prior art keywords
hydrogel
gelatin
medical device
liposomal
therapeutic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US09/849,481
Inventor
Frank DiCosmo
Valerio DiTizio
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to US09/849,481 priority Critical patent/US20020051812A1/en
Publication of US20020051812A1 publication Critical patent/US20020051812A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/52Hydrogels or hydrocolloids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/28Materials for coating prostheses
    • A61L27/34Macromolecular materials
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/54Biologically active materials, e.g. therapeutic substances
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L29/00Materials for catheters, medical tubing, cannulae, or endoscopes or for coating catheters
    • A61L29/08Materials for coatings
    • A61L29/085Macromolecular materials
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L29/00Materials for catheters, medical tubing, cannulae, or endoscopes or for coating catheters
    • A61L29/14Materials characterised by their function or physical properties, e.g. lubricating compositions
    • A61L29/145Hydrogels or hydrocolloids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L29/00Materials for catheters, medical tubing, cannulae, or endoscopes or for coating catheters
    • A61L29/14Materials characterised by their function or physical properties, e.g. lubricating compositions
    • A61L29/16Biologically active materials, e.g. therapeutic substances
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/127Liposomes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/404Biocides, antimicrobial agents, antiseptic agents
    • A61L2300/406Antibiotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/412Tissue-regenerating or healing or proliferative agents
    • A61L2300/414Growth factors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/42Anti-thrombotic agents, anticoagulants, anti-platelet agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/43Hormones, e.g. dexamethasone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/432Inhibitors, antagonists
    • A61L2300/436Inhibitors, antagonists of receptors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/60Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
    • A61L2300/62Encapsulated active agents, e.g. emulsified droplets
    • A61L2300/626Liposomes, micelles, vesicles

Definitions

  • the present invention is directed to an effective drug delivery vehicle involving the containment of a therapeutic agent within a hydrogel, which hydrogel is then bound to a substrate.
  • the substrates of the present invention include any in-dwelling medical device or implant, wound dressings, wound closures, and the like.
  • the present invention further provides means for compounding such hydrogels and affixing such hydrogels to a substrate.
  • Nosocomial bacteriuria is the most common infection contracted in long-term care facilities and is usually associated with catheterization. The condition is virtually universal in patients after thirty days of catheterization. Complications will include fever, acute and chronic pyelonephritis, bacteremia and renal stones. The extra-lumenal surface of the catheter may become colonized with bacteria and act as a conduit for bacterial entry into the bladder. The best preventative measure is to limit the use of long-term in-dwelling catheters; this is often not possible. J. W. Ward, Warren “Management of patients in long-term care facilities with catheter-associated bacteriuria if catheterized for a long enough period.
  • Catheter-related septicemia occurs in approximately 400,000 of the estimated five million Americans who are catheterized each year. Treatment for a single event of catheter-related septicemia in a critically ill patient adds approximately 6.5 days to a stay in an intensive care unit and will cost about $29,000. I. R. Raad and R. O. Darouchie, “Catheter-related septicemia: risk reduction.” Infect Med 13:807-812, 815-816, 823 (1996). Indeed, catheter-related septicemia represents the most common life-threatening complication associated with intravascular catheters. There is a strong relationship between catheter-site inflammation and the recovery of bacteria from the surface of the device. In situ, the catheter surface becomes colonized with opportunistic microbial pathogens, and these colonies become the source of infections.
  • a common source for catheter colonization and catheter-related sepsis is the skin insertion site. Indeed, the skin surface is the most common source of short-term catheter colonization and subsequent infection. Catheter-related infections remain a significant problem in healthcare facilities. It is generally accepted that no method has yet emerged for the adequate and satisfactory management of catheter-related infection.
  • the adhesion of microorganisms to the catheter surface is related to the interaction of the host, the microorganisms and the catheter material.
  • the host tissue reacts to the catheter material as a foreign body and deposits a thrombin coat over the material, which becomes colonized with microbes, often within 24 hours; this coating of protein and microorganisms is called a biofilm.
  • microbes find a suitable niche for continued growth as well as for protection from antibiotics, phagocytic neutrophils, macrophages and antibodies.
  • U.S. Pat. No. 4,442,133 there is disclosed a process for vascular prostheses with a cationic surfactant, e.g. tridodecylmethyl-ammonium chloride (TDMAC), to increase sites for antibiotic bonding.
  • a cationic surfactant e.g. tridodecylmethyl-ammonium chloride (TDMAC)
  • TDMAC tridodecylmethyl-ammonium chloride
  • U.S. Pat. No. 4,749,585 provides a method for coating a prosthesis with an ionically charged surfactant and an antibiotic compound encapsulated within phospholipid vesicles, wherein said vesicles have a surface charge opposite to that of said surfactant.
  • the drawback of this system is that the amount of liposomes coated on to the surface is generally low, not allowing for a therapeutic dose of drug to be retained on the device for periods of time necessary to suppress or alleviate the infection.
  • Second, upon insertion of a device, such as a catheter so treated it is expected that the surface coating of ionically bound liposomes will be sheared off from the area where the liposomes were intended to reside.
  • Wachol-Drewek et al. 1996, Biomaterials 17:1733-1738 disclose the use of collagen implants of various structures and a gelatin sponge which were placed in antibiotic solutions and allowed to absorb the compounds. They concluded: “If an implant that has a protective effect against wound infections over a period of 24-48 h is required, the materials described here are suitable. However, where treatment in infected areas should ensure antibiotic cover for 5-10 d[days] neither collagen materials immersed in antibiotics nor collagen sponges containing gentamicin are suitable.”
  • Photoreactive surface modification of fabricated devices is described in Matsuda & Inoue 1990 (Trans Am Soc Artif Intern Organs, Poster Session 1, Biomaterials , pp. M161-M164).
  • Nakayama & Matsuda 1992 ( ASAIO Journal 38:M421-424) describe the incorporation of heparin, useful as a thromboresistant molecule, within a hydrophilic co-polymer of poly(N,N-dimethylacrylamide)-poly(2-cinnamoylethyl methacrylate) linked to a polyethylene terephthalate surface using a photochemical process; poly(m-azidostyrene) was initially applied to the polyethylene terephalate surface to provide a reactive interface.
  • the type of drug incorporated into the hydrogel formulation is not restricted to any single antibiotic, or combination of one or more of these.
  • the hydrogel composition might comprise a variety of active agents including antibiotics, hormones, growth factors and other factors that are beneficial for the condition under management, in accordance with sound medical judgement.
  • the present invention avails the use of antibiotic-loaded liposomes sequestered within a biocompatible hydrogel retained on the surface of the biomedical device, e.g. catheter.
  • Liposomes, microspheres, nanospheres, biodegradable polymers, and other systems are excellent drug delivery vehicles; and the methods of preparation and drug loading procedures for liposomes and the others are well-known in the art.
  • Liposomes can store both apolar and polar compounds via interactions with the biocompatible and biodegradable lipid bilayer, or compartmentation within the aqueous core, respectively.
  • a method for producing a biofilm-resistant surface might involve the binding of antibiotic-containing liposomes directly to the surface. Theoretical calculations however, indicate that if a surface was saturated with drug-carrying liposomes, only about 150 ng of the antibiotic ciprofloxacin could be localized per square centimeter of surface. Nanogram quantities of ciprofloxacin are unlikely to provide protection from microbes over substantial periods of time, e.g. several days or more. We have devised a means to effectively exploit the space above the catheter's surface to significantly increase the surface area concentration of bound liposomal antibiotic. Specific formulation of the liposome bilayer allows for drug release over a period ranging from days to weeks. See, e.g., R.
  • the method of the present invention provides for co-valently attaching liposomes to a substrate such as a catheter, or other liquid-flow conduit, or other device, such as a wound dressing.
  • the method exploits the surface area of the device as well as the volume occupied by the hydrogel matrix bonded to the surface.
  • the volume of gel matrix can accommodate large quantities of drug-loaded liposomes, microspheres, nanospheres, or other drug carrier and consequently, relatively high doses of a therapeutic drug can be deposited at specific sites.
  • the hydrogel matrix is biocompatible and biodegradable (i.e.
  • the containment of the liposomes within the gel matrix also creates an opportunity to control drug diffusion rates, thereby affording long-term drug efflux.
  • the present invention includes a method for loading efficacious quantities of a liposomal therapeutic agent on a medical device by mixing said liposomal therapeutic agent with a hydrogel, and covalently binding said hydrogel to a pre-formed polymeric surface of a medical device.
  • pre-formed polymeric surface is meant that the polymeric material used in fabricating the medical device is formed or manufactured in advance of the covalent attachment of the hydrogel.
  • covalent attachment of the hydrogel to the polymeric material can be effected through the use of a bifunctional linker molecule, preferably one comprising an azide functional group.
  • the pre-formed polymeric surface is a silicone rubber.
  • One such embodiment is a silicone catheter loaded with a co-valently bonded polyethylene glycol-gelatin matrix containing a liposomal antibiotic-carrier coating to control catheter-related infections, such as bacteriuria and septicemia.
  • Medical devices where the coating can be used include catheters, wound closures, surgical dressings, temporary orthopedic implants and others.
  • the liposomal hydrogel of the present invention includes a variety of hydrogel drug combinations. Generally, the selection or pairing of the hydrogel and drug is determined only by the desired application and relevant indication. That is, any active agent that can be compounded into liposomes, microspheres, nanospheres, or other suitable encapsulation vehicle can be confined within the hydrogel matrices of the present invention to create the therapeutic hydrogels of the present invention. Those hydrogels can then be affixed to a substrate such as the surface of a catheter or other in-dwelling liquid conduit, or the substrate or matrix of a wound closure or wound dressing material.
  • One embodiment of the present invention involves the deposition and co-valent attachment of a polyethylene glycol-gelatin matrix layer to the surface of in-dwelling biomedical implants (e.g. catheters, stents, intravenous tubes, dialysis tubes, orthopedic implants, surgical sponges and wound dressings, etc.) and the sequestration or co-valent attachment of liposomes to the constituents of the matrix.
  • the liposomes contain a therapeutic.
  • the matrix thus constitutes a vehicle for the containment of high concentrations of therapeutic agent such as one or more antibiotics, hormones, steroids, growth factors, antihistamines, colony stimulating factors, interleukins, and the like, and/or combinations thereof.
  • the therapeutic hydrogels of the present invention can be used in the management of tissue and biomaterial associated infection.
  • the matrix can be a hydrogel (e.g., gelatin, pectin, etc.), a protein (e.g. collagen, hemoglobin, etc.), or other adjuvant.
  • the matrix will have some structural integrity as by cross-linking or similar structural support to impart resistance to shear forces resulting from insertion of the device.
  • the present invention provides a medical device having a polymeric substrate; a matrix material covalently bound to said substrate; and a liposomal therapeutic agent confined within said matrix material.
  • the matrix material can be a hydrogel, a protein, or other suitable adjuvant.
  • the matrix material will preferably be a cross-linked material.
  • One example is gelatin cross-linked with polyethylene glycol as by reacting gelatin with bis-(amine)-PEG.
  • Matrix material can be covalently bound to a substrate by a variety of means.
  • a protein such as gelatin can be derivatized with a bifunctional linker molecule such as 4-azido-2,3,5,6-tetrafluorobenzoic acid That is, the carbonyl carbon of the benzoic acid group can be made to react with a free amine of a protein to form an amide; the azido functionality can be made to react with a methylene carbon of the silicone rubber. In this manner, the matrix material is covalently bonded to the substrate.
  • a bifunctional linker molecule such as 4-azido-2,3,5,6-tetrafluorobenzoic acid That is, the carbonyl carbon of the benzoic acid group can be made to react with a free amine of a protein to form an amide; the azido functionality can be made to react with a methylene carbon of the silicone rubber. In this manner, the matrix material is covalently bonded to the substrate.
  • the therapeutic hydrogels of the present invention serve as support material for a variety of liposomal therapeutics.
  • Any therapeutic agent suitable for encapsulation in a liposome, microsphere, nanosphere or the like can be utilized in the present invention.
  • therapeutic agents useful in the present invention include antibiotics, antihistamines, hormones, steroids, therapeutic proteins, and the like.
  • the desired concentration of active agent within a hydrogel loaded on a substrate will vary depending upon the characteristics of the chosen active agent. For example, as between an antibiotic and a therapeutic protein, the required concentration of antibiotic, which are generally active in the microgram range, will likely be higher than the concentration of a therapeutic protein, many of which are active in the nanogram range. Other standard dosing criteria will also be considered in selecting the concentration ranges of active agent loaded onto the substrate in accordance with standard practice in the art.
  • a preferred embodiment of the present invention is a gelatin hydrogel cross-linked with polyethylene glycol (PEG); and dispersed within the hydrogel is a liposomal antibiotic such as ciprofloxacin.
  • PEG polyethylene glycol
  • Ciprofloxacin has been shown to exhibit good activity against a broad spectrum of bacteria, particularly those associated with urinary tract infections.
  • Such embodiments provide dramatically improved in-dwelling medical devices.
  • Medical devices of the present invention can be loaded with as much as 1000 ⁇ g/cm 2 ciprofloxacin.
  • Preferred embodiments have about 10-300 ⁇ g/cm 2 ; and still more preferred embodiments have about 25-200 ⁇ g/cm 2 .
  • the present invention avails long-term, slow release of an anti-infective active agent from an in-dwelling medical device; and dramatically reduces the frequency with which such in-dwelling medical devices must be removed and replaced.
  • the PEG-gelatin-liposome mixture can be effectively applied to the surface of a silicone Foley catheter that has been pre-treated with phenylazido-modified gelatin. Methods for immobilization of photoreactive gelatin on the catheter's surface are presented herein. Use of silicone devices is not a limiting feature, as any such polymeric device can be treated to harbor a hydrogel in which liposomes, or other drug carriers are sequestered.
  • the present invention provides a method for associating substantial quantities of antibiotic-releasing liposomes with a silicone Foley catheter through their inclusion in a surface-coating of PEG-gelatin hydrogel covalently linked to the silicone surface, and the antibiotic was released to the surrounding area over a period of greater than five days.
  • Modifications of the technique should allow it to be applied to other medical devices as well, such as, intraperitoneal catheters, joint and vascular prostheses, and reconstructive implants.
  • An attractive feature of this system is the possibility of sustained release of compounds having a range of chemical properties, such as antibiotics, enzymes, growth factors, human hormones, anticoagulants, etc.
  • the surface characteristics of the PEG-gelatin hydrogel will improve biocompatibility of the device as hydrogel-coated catheters tend to minimize the inflammation associated with the presence of any foreign object in the body.
  • J. N. Nacey and B. Delahunt “Toxicity study of first and second generation hydrogel-coated latex urinary catheters,” Br. J. Urol., 67:314-316 (1991).
  • the inclusion of gelatin in our hydrogel system will lead to its eventual degradation in vivo leaving a co-valently-bonded surface layer of AFB-gelatin that should be relatively resistant to further protease digestion.
  • T. Okada and Y. Ikada “In vitro and in vivo digestion of collagen covalently immobilized onto the silicone surface,” J. Biomed. Mater. Res., 26:1569-1581 (1992). It is possible that the remaining layers of gelatin will facilitate better integration of the catheter with the surrounding tissue.
  • the liposomal matrix materials of the present invention can be used to prevent or treat patients at risk of or suffering from biofilm mediated infection or other forms of infection associated with in-dwelling medical devices, wound closures, and the like.
  • the method comprises inserting into a patient a medical device of the present invention, said medical device comprising a substrate, as for example, a silicone rubber substrate, and covalently bound to said substrate is a hydrogel within which is dispersed a liposomal therapeutic material such as an antibiotic.
  • the method comprises replacing infected medical devices with the medical devices of the present invention.
  • hydrogel or gel any material forming, to various degrees, a jelly-like product when suspended in a solvent, typically water or polar solvents.
  • a solvent typically water or polar solvents.
  • These gels can be proteins such as collagen or hemoglobin, or more conventional hydrogels such as gelatin, pectin, and fractions and derivatives thereof.
  • liposomal therapeutic agents any physical structure surrounding or encapsulating a therapeutic agent such as a drug.
  • liposomal therapeutic agents will include various drugs or biologically active agents such as antibiotics, antihistamines, hormones, steroids, growth factors, colony stimulating factors, interleukins, and the like confined or encapsulated within a structure such as a liposome, whether of unilamellar or bilayer structure, or microspheres or nanospheres or the like.
  • a bifunctional linker molecule is any molecule possessed of at least two functional groups that can chemically react with and form covalent bonds with other functional groups or chemical substituents such as the free amines of proteins and the like.
  • the bifunctional linker will have an aryl amine functionality, as in an aroyl azide group, and a carbonyl functionality, as in a carboxylic acid group.
  • NHS-AFB was prepared as described in J. F. W. Keana and S. X. Cai, “New reagents for photoaffinity labeling and photolysis of functionalized perfluorophenyl azides,” J. Org. Chem., 55:3640-3647 (1990) using the coupling agent DCC.
  • AFB-gelatin of varying degrees of substitution was synthesized by the addition of NHS-AFB in methanol to a solution of gelatin (0.5-1.0%) in 50 mM Borate buffer (pH 8.6). The mixture was incubated overnight at room temperature with stirring.
  • Gelatin was iodinated using Iodo Beads (Pierce, Rockford, Ill.) according to the supplier's directions.
  • Iodo Beads Pierce, Rockford, Ill.
  • 100 ⁇ g of gelatin 500 ⁇ L of 0.2 mg/mL gelatin in Hepes buffered saline, pH 7.4 (HBS)
  • HBS Hepes buffered saline
  • Na 125 I (1 mCi from Amersham Canada, Oakville, ON) was added to the reaction vial and left to react for 15 minutes. Transfer of the protein to a second vial terminated the reaction.
  • the reaction vial was washed with three 0.5 mL aliquots (200 ⁇ g/mL) of unlabeled gelatin.
  • the protein solution (approx. 400 ⁇ g in 2.1 mL of HBS) was dialyzed in 200 mL of buffer until the dialysate was minimally radioactive (approx. 48 hrs with 5 changes of medium).
  • the specific activity of the iodinated gelatin was determined by a technique that exploits the insolubility of the complex formed between gelatin and the dye Sirius Red in acetic acid
  • Four 50 ⁇ L aliquots were removed from the iodinated protein solution and added to 1.5 mL polypropylene centrifuge tubes, followed by the addition of 50 ⁇ L of HBS and 1 mL of Sirius Red (50 ⁇ M) in 0.5 M acetic acid.
  • the tubes were incubated at room temperature for 30 minutes and subsequently centrifuged at 12,000 ⁇ g for 30 minutes. The supernatant was removed and a portion (0.5 mL) was used for protein quantitation via the decrease in absorbance (540 nm) of the dye remaining in solution.
  • the protein/dye pellet was resuspended with three 150 ⁇ L washes of 0.2 N NaOH containing 2 mg/mL gelatin.
  • the radioactivity of the eluate was measured in a liquid scintillation counter. Control experiments indicated that the presence of Sirius Red in the scintillation fluid did not interfere with the determination of 125 I radioactivity.
  • Residual adsorbed protein was measured by cutting the centrifuge tubes into quarters and placing them in scintillation vials for counting. The specific activity was calculated to be 0.12 ⁇ 0.01 ⁇ Ci/ ⁇ g. This level of labeling is consistent with the paucity of tyrosine and histidine residues in gelatin.
  • Radioiodinated gelatin was modified with AFB as described above, however, the coupling solution and dialysis medium consisted of HBS (pH 8.0 and 7.4, respectively). The ratio of NHS-AFB to gelatin in the coupling solution was 1:4 (w/w). Following dialysis, the volume of the AFB-( 125 I)gelatin solution was made up to 5 mL and the protein concentration was determined to be 3.9 ⁇ 0.6 ng/ ⁇ L. Aliquots (10 ⁇ L each) of radioiodinated AFB-gelatin were applied to the side of silicone rectangles corresponding to the outer surface of the original catheter. All sections (12 in total) were dried under vacuum for 90 minutes.
  • Liposomes were composed of DPPC/Cholesterol/PEG-DSPE/Rhodamine-DPPE in a 1:1:0.05:0.001 ratio.
  • the formulation to be used is not limiting, and any number of lipid-to-other-constituents ratios may be used to effectively achieve the embodiments of this invention.
  • the lipids were dissolved in 4 mL of chloroform and the solvent was removed in vacuo. The resulting lipid film was placed under vacuum for two hours and subsequently hydrated with 1 mL of 250 mM ammonium sulfate (pH 2.5) at 45° C. Liposomes were then frozen in liquid nitrogen and thawed in a 45° C.
  • PEG-gelatin solutions consisted of 10% gelatin, 6% NP-PEG and 10% sucrose at pH 4.0. If liposomes were required, they were added from a pure liposome suspension. The concentration of liposomes in PEG-gelatin solutions was 15 mM with respect to DPPC. All solutions were heated at 45° C. for 15 min. to dissolve gelatin.
  • the PEG-gelatin matrix was also crosslinked by the formation of amide bonds between bis-(amine)-PEG and the free carboxyl groups of gelatin.
  • the silicone catheter surface is immersed in a solution of aqueous soluble carbodiimide (2 mg/mL) and incubated at room temperature for 30 min.
  • the reaction of the activated carboxyl groups with PEG and gelatin amino moieties is initiated by submersing the silicone material in borate buffer (200 mM, pH 8.5). Incubation in the alkaline buffer proceeds for 2 hr.
  • the silicone surface is placed in 10% sucrose solution for 6 hr, with three changes of medium, to remove non-crosslinked material.
  • This treatment results in a crosslinked PEG-gelatin gel that retains its integrity and remains affixed to the catheter for at least seven days when placed in a 37° C. solution of 10% sucrose.
  • the crosslinking chemistry is outlined in FIG. 4.
  • Residual p-nitrophenol was leached from the gels by incubation at room temperature in 10% sucrose (pH 4.0) for 12 hrs, with four changes of medium. The absence of p-nitrophenol was confirmed by negligible absorbance of the dialysate at 410 nm.
  • Catheter pieces were placed in 10% sucrose solution (pH 7.5) containing 2 mM ciprofloxacin, while for liposomes in suspension, an appropriate amount of drug was added to make the suspension 2 mM in ciprofloxacin. Incubation in both cases proceeded for 1 hour at 45° C. The liposome suspension was centrifuged at 3000 ⁇ g for 5 minutes to pellet drug crystals and the supernatant was then applied to a G-50 column (1 ⁇ 10 cm) to remove unentrapped ciprofloxacin.
  • Dehydrated hydrogels were prepared by drying coated catheter sections in an oven at 35° C. for 2.5 hr. The dried gels were then rehydrated in Tris buffer (10 mM Tris, 110 mM NaCl, pH 7.4) or in concentrated ciprofloxacin-HCl solution (25 mg/mL) as required. The temperature during the rehydration process was maintained at 45° C.
  • Ciprofloxacin Loading into Liposomes and PEG-Gelatin Gel Sample Total Ciprofloxacin Entrapped PEG-Gelatin Gel a 42 ⁇ 12 ⁇ g/cm 2 PEG-Gelatin-liposome Gel a 185 ⁇ 16 ⁇ g/cm 2 PEG-Gelatin-Liposome Gel b 3083 ⁇ 267 ⁇ g/cm 3 Dry PEG-Gelatin-Liposome Gel a 173 ⁇ 6 ⁇ g/cm 2 Dry PEG-Gelatin Gel a,c 1253 ⁇ 80 ⁇ g/cm 2 Dry PEG-Gelatin-Liposome Gel a,c 1298 ⁇ ⁇ g/cm 2 Liposomes-only 0.52 ⁇ 0.04 ⁇ mol cipro/ ⁇ mol lipid
  • the quantity of therapeutic agent loaded on the substrate can be increased or decreased over greater ranges than those shown in Table I. Greater concentrations of therapeutic agent can be loaded by increasing the amount of drug encapsulated and mixed into the hydrogel. For example, we expect that concentrations up to about 1,000 ⁇ g (1.0 mg) per cm 2 or more of an antibiotic active agent can be loaded on substrates with the methods of the present invention; and that concentrations of up to about 10,000 ⁇ g/cm 3 or more can be loaded on substrates. A preferred concentration range of antibiotic loaded on such substrates is about 10-1,000 ⁇ g/cm 2 . A preferred range for ciprofloxacin is about 10-200 ⁇ g/cm 2 .
  • the release experiment was initiated by placing each catheter section or dialysis membrane (containing liposome suspension 2.7 mM in DPPC) into separate liquid scintillation vials filled with 15 mL of Tris buffer. At selected time intervals 3 mL was removed from each vial for ciprofloxacin quantitation via a fluorescence-based assay using an excitation wavelength of 324 nm, an emission wavelength of 450 nm, and 5 nm slit widths. The amount of ciprofloxacin present was determined by comparisons to a standard curve. The remaining solution in the vials was emptied and replaced with 15 mL of buffer. The samples were incubated at 37° C. throughout the experiment.
  • PBS glycerol-phosphate buffered saline
  • Catheter sections were aseptically placed in 100 mL of sterile nutrient broth (Difco, Detroit, Mich.) contained within a 250 mL glass beaker. Twelve catheter sections from each coating formulation were added to individual beakers. The P. aeruginosa culture was washed 3 times in a pH 7.1 PBS solution, then inoculated to each of the beakers. The inoculum size was sufficient to yield 1.5 ⁇ 0.5 ⁇ 10 7 cfu/mL in the 100 mL volume. The inoculated catheter suspensions were then placed in an incubator maintained at 37° C. and agitated at a rate of 100 rpm.
  • sterile nutrient broth Difco, Detroit, Mich.
  • the catheter sections were removed from the bacterial suspensions and individually rinsed with a 10 mL volume of sterile PBS delivered via a gravity feed from a 10 mL pipet.
  • the rinsed sections were placed in 20 mL plastic test tubes containing 5 mL volumes of sterile PBS and 3 mm diameter glass beads.
  • the catheter sections were vortexed for 1 minute at high speed. The sonication and vortexing procedure was repeated three times. Aliquots were then removed from each of the suspensions and plated to nutrient agar. The plates were incubated at 37° C. for 48 h.
  • the modification of the silicone catheter surface in this example used the photoreactive molecule 4-azido-2,3,5,6-tetrafluorobenzoic acid (AFB). It can be linked to the amino groups of gelatin via N-hydroxysuccinimide (NHS) chemistry. Based on the amino acid composition of ox hide gelatin, (J. E. Eastoe and A. A. Leach, “Chemical constitution of gelatin,” in Science and Technology of Gelatin , A. G. Ward and A. Courts (eds.), Academic Press, New York, 1977, pp. 73-107) the typical gelatin molecule (MW 75,000) contains approximately 25 ⁇ -amino groups derived from lysine and hydroxylysine.
  • AZA 4-azido-2,3,5,6-tetrafluorobenzoic acid
  • AFB fluorinated aryl azide
  • Ciprofloxacin release rates were determined for the following samples: liposomes-only, PEG-gelatin hydrogel alone, a liposomal PEG-gelatin hydrogel, and a drug-containing liposomal hydrogel that was air dried and then rehydrated with pH 7.4 Tris buffer. All the liposomes used in this study contained DPPC and cholesterol. PEG-lipid was also included to avoid gelatin-induced destabilization of the bilayer and to increase immobilization of the liposomes within the hydrogel matrix via stearic interactions. The results of the experiment are summarized in FIG. 2. The quantity of ciprofloxacin released at a given time point is expressed as a percentage of the total amount released throughout the experiment. There are two notable trends. The hydrogel-only, and rehydrated liposomal hydrogel treatments were not successful in retaining ciprofloxacin for a sustained period of time; almost all of the drug initially incorporated was released within the first two hours.
  • hydrogels rehydrated in concentrated ciprofloxacin solution retained very large quantities of antibiotic (approx. 1.4 mg/ 1 cm catheter section). Almost all (>99%) of the hydrogel-associated ciprofloxacin was released after the first four hours of incubation, as expected from an analysis of the prior art.
  • Ciprofloxacin was incorporated into dried liposomal hydrogels during the rehydration step since our data indicated that pre-loaded liposomes embedded in a hydrogel were destabilized by dehydration. In effect, antibiotic was encapsulated within liposomes as they reformed during the rehydration of the PEG-gelatin film. Our calculations indicate that the encapsulation efficiency of ciprofloxacin in liposomes generated in situ was 7% relative to the amount of ciprofloxacin in pre-formed liposomes. The variation can be accounted for by the different loading techniques used. In general, compounds are more efficiently concentrated within liposomes when using a remote-loading technique exploiting pH and ammonium sulfate gradients than when a lipid film hydration method is employed.
  • the optimal efflux profile in terms of prolonged release of substantial antibiotic quantities was obtained from liposomal hydrogel samples that were not dehydrated.
  • the hydrogel system was shown to be capable of releasing substantial quantities of drug for up to 7 days. It is possible to improve the amount and duration of release by increasing the concentration of liposomes within the hydrogel; this aspect is not limiting. For example, the concentration can be at least doubled without affecting hydrogel stability. Increasing the liposome concentration allows the air dried liposomal hydrogel system to become a viable alternative as this compensates for the decrease in drug encapsulation efficiency associated with the in situ generation of liposomes. Alternatively, a dried liposomal hydrogel with suitable sustained release properties as presented here may be obtained by the development of a lyophilization protocol.
  • a practical aim of this invention is toward a catheter, or any polymeric biomedical device coating capable of resisting colonization by bacteria and subsequent infection in vivo and during application.
  • untreated, PEG-gelatin coated, and ciprofloxacin-containing liposomal hydrogel catheter sections were challenged with a clinical strain of P. aeruginosa known to form biofilms on silicone catheters.
  • the hydrogel coating containing antibiotic liposomes was effective in preventing cells from adhering and remaining viable.
  • the number of viable bacteria in the broth containing these sections was approximately 6.7 ⁇ 10 2 cfu/mL at the end of the experiment.
  • DPPC dipalmitoylphosphatidylcholine
  • PEG-DSPE PEG-distearoylphosphatidylethanolamine
  • Rhodamine dipalmitoylphosphatidylethanolamine Rhodamine-DPPE
  • 4-azido-2,3,5,6-tetrafluorobenzoic acid were purchased from Molecular Probes (Eugene, Oreg.).
  • Porcine gelatin-a MW 50,000-100,000
  • NP-PEG polyoxyethylene bis(p-nitrophenyl carbonate)
  • cholesterol were obtained from Sigma (St. Louis, Mo.).
  • Fluorescamine, 1,3-dicyclohexylcarbodiimide (DCC), N-hydroxysuccinimide (NHS), and Sirius Red were purchased from Aldrich (Milwaukee, Wis.). All reagents and solvents were of analytical grade and were used without further purification. Deionized water (Milli-Q, Millipore, Bedford, Mass.) filtered through a 0.22 ⁇ m membrane was used in all experiments. Ciprofloxacin (Bayer, Germany) was analyzed in a Perkin Elmer LS-50 fluorimeter. Sirius Red and p-nitrophenol were quantitated using a Hewlett-Packard 8450 spectrophotometer.
  • Silicone Foley catheters (Sherwood Medical, St. Louis, Mo.) were prepared for use by sectioning into cylinders (3 mm diameter and 10 mm length). The open ends of the sections were sealed with silicone rubber (RTV 108, GE, Pickering, ON). Occasionally, cylindrical sections were further subdivided into rectangular pieces (5 mm ⁇ 3 mm). Silicone sections were cleaned prior to each experiment by refluxing in methanol for six hours.

Abstract

The present invention is directed to a vehicle for effecting drug delivery from a solid substrate. Hydrogels loaded with liposomal therapeutic agents such as antibiotics are covalently bonded to the surface of substrates such as in-dwelling medical devices, such as implants, catheters, and the like. The present invention is particularly useful in the treatment and prevention of biofilm mediated infection often associated with the use of in-dwelling medical devices.

Description

    CROSS REFERENCE TO RELATED APPLICATIONS
  • This application is a continuation-in-part of U.S. application Ser. No. 08/631,326 filed Apr. 12, 1996.[0001]
  • FIELD OF THE INVENTION
  • The present invention is directed to an effective drug delivery vehicle involving the containment of a therapeutic agent within a hydrogel, which hydrogel is then bound to a substrate. The substrates of the present invention include any in-dwelling medical device or implant, wound dressings, wound closures, and the like. The present invention further provides means for compounding such hydrogels and affixing such hydrogels to a substrate. [0002]
  • BACKGROUND OF THE INVENTION
  • The control of infection acquired in a clinical setting is a major and significant health care problem. Infections contracted during patient treatment within healthcare facilities have been estimated to contribute to ninety-thousand (90,000) deaths and cost $12 Billion dollars U.S. to treat per annum. [0003]
  • Nosocomial bacteriuria is the most common infection contracted in long-term care facilities and is usually associated with catheterization. The condition is virtually universal in patients after thirty days of catheterization. Complications will include fever, acute and chronic pyelonephritis, bacteremia and renal stones. The extra-lumenal surface of the catheter may become colonized with bacteria and act as a conduit for bacterial entry into the bladder. The best preventative measure is to limit the use of long-term in-dwelling catheters; this is often not possible. J. W. Ward, Warren “Management of patients in long-term care facilities with catheter-associated bacteriuria if catheterized for a long enough period. [0004]
  • Catheter-related septicemia occurs in approximately 400,000 of the estimated five million Americans who are catheterized each year. Treatment for a single event of catheter-related septicemia in a critically ill patient adds approximately 6.5 days to a stay in an intensive care unit and will cost about $29,000. I. R. Raad and R. O. Darouchie, “Catheter-related septicemia: risk reduction.” [0005] Infect Med 13:807-812, 815-816, 823 (1996). Indeed, catheter-related septicemia represents the most common life-threatening complication associated with intravascular catheters. There is a strong relationship between catheter-site inflammation and the recovery of bacteria from the surface of the device. In situ, the catheter surface becomes colonized with opportunistic microbial pathogens, and these colonies become the source of infections.
  • A common source for catheter colonization and catheter-related sepsis is the skin insertion site. Indeed, the skin surface is the most common source of short-term catheter colonization and subsequent infection. Catheter-related infections remain a significant problem in healthcare facilities. It is generally accepted that no method has yet emerged for the adequate and satisfactory management of catheter-related infection. [0006]
  • The adhesion of microorganisms to the catheter surface is related to the interaction of the host, the microorganisms and the catheter material. The host tissue reacts to the catheter material as a foreign body and deposits a thrombin coat over the material, which becomes colonized with microbes, often within 24 hours; this coating of protein and microorganisms is called a biofilm. In the biofilm, microbes find a suitable niche for continued growth as well as for protection from antibiotics, phagocytic neutrophils, macrophages and antibodies. [0007]
  • There have been numerous attempts to produce biomedical products that impede or prevent infection. Biomedical products that incorporate and release silver compounds for infection control have been studied for many years. However, clinical studies of these products, including catheters, have shown only minor improvements in infection control. The devices have been described to exhibit resistance to infection, but in practical application fail to adequately inhibit infection. [0008]
  • Ciresi et al. 1996 ( Am Surg 62:641-646) compared the incidence of catheter-related infection and catheter-related sepsis between a standard catheter and the recently released Arrowgard™ catheter in a clinical trial with one-hundred-ninety-one patients receiving total parenteral nutrition. The Arrowgard™ catheter contains a combination of silver sulfadiazine and chlorhexidine, that is thought to render the catheter surface resistant to bacterial colonization and subsequent sepsis. The authors concluded that the coating of the central venous catheters with sulfadiazine and chlorhexidine does not reduce the rate of catheter-related infection or catheter-sepsis when compared with a standard central venous catheter in patients receiving total parenteral nutrition. [0009]
  • Hasaniya et al. 1996 ([0010] Chest 109:1030-1032) found that the use of an attachable subcutaneous silver-impregnated cuff failed to decrease the incidence of central venous catheter-related infection and sepsis.
  • In U.S. Pat. No. 4,442,133 there is disclosed a process for vascular prostheses with a cationic surfactant, e.g. tridodecylmethyl-ammonium chloride (TDMAC), to increase sites for antibiotic bonding. Before the prostheses are used they are dipped or coated in a solution of TDMAC to adsorb the antibiotic. [0011]
  • Stickler et al. 1994 ([0012] Cells and Materials 4:387-398), conclude that pretreatment by adventitious coating of catheters with ciprofloxacin (an antibiotic) is unlikely to prevent bacterial biofilm formation on long-term, in-dwelling silicone or silicone-coated latex urethral catheters.
  • U.S. Pat. No. 4,749,585 provides a method for coating a prosthesis with an ionically charged surfactant and an antibiotic compound encapsulated within phospholipid vesicles, wherein said vesicles have a surface charge opposite to that of said surfactant. The drawback of this system is that the amount of liposomes coated on to the surface is generally low, not allowing for a therapeutic dose of drug to be retained on the device for periods of time necessary to suppress or alleviate the infection. Second, upon insertion of a device, such as a catheter so treated, it is expected that the surface coating of ionically bound liposomes will be sheared off from the area where the liposomes were intended to reside. [0013]
  • Oloffs et al 1994; [0014] Biomaterials 15:753-758, describe the biocompatibility of silver-coated polyurethane catheters and silver coated Dacron® material to inhibit infection. These fail to inhibit catheter-related bacterial infection at the infection site (vide supra).
  • Schierholz, J. et al. 1994; [0015] Biomaterials 15:996-1000, disclose the incorporation of antibiotic into an antibiotic releasing silicone ventricle catheter to prevent shunt infection. The antibiotic (rifampicin) was added to the swelling-activated polydimethylsiloxane matrix and would diffuse from the matrix.
  • Wachol-Drewek et al. 1996, [0016] Biomaterials 17:1733-1738, disclose the use of collagen implants of various structures and a gelatin sponge which were placed in antibiotic solutions and allowed to absorb the compounds. They concluded: “If an implant that has a protective effect against wound infections over a period of 24-48 h is required, the materials described here are suitable. However, where treatment in infected areas should ensure antibiotic cover for 5-10 d[days] neither collagen materials immersed in antibiotics nor collagen sponges containing gentamicin are suitable.”
  • Several studies have used photoactivated surface modification in attempts to improve the biocompatibility of biomedical devices. The synthesis of phenylazido-derivatized substances and photochemical surface immobilization of functional groups is presented by Sugawara & Matsuda ([0017] J Biomed Mater Res 32:157-164).
  • The surface modification of silicone by corona discharge for the immobilization of various proteins is disclosed by Okada et al. 1987 ([0018] Biomaterials and Clinical Applications, pp. 465-470, Pizzoferrato, A., Marchetti, P. G., Ravglioli, A., & Lee, A.J.C. Elsevier Scientific Publishers, Amsterdam).
  • Photoreactive surface modification of fabricated devices is described in Matsuda & Inoue 1990 (Trans Am Soc Artif Intern Organs, [0019] Poster Session 1, Biomaterials, pp. M161-M164). Nakayama & Matsuda 1992 (ASAIO Journal 38:M421-424) describe the incorporation of heparin, useful as a thromboresistant molecule, within a hydrophilic co-polymer of poly(N,N-dimethylacrylamide)-poly(2-cinnamoylethyl methacrylate) linked to a polyethylene terephthalate surface using a photochemical process; poly(m-azidostyrene) was initially applied to the polyethylene terephalate surface to provide a reactive interface. The procedure produces a cross-linked matrix in which heparin is retained. Sigrist et al. (Optical Eng. (1995) 34:2339-2347) describe surface immobilization of biomolecules by light. Aldenhoff & Koole (J. Biomed. Mate. Res. (1995) 29:917-928) describe a method for the photoimmobilization of protein to polyurethane surfaces.
  • The clinical problem remains that the catheter-related biofilm mediated infection can only be adequately treated by surgical intervention and removal of the bacterial-laden device followed with antibiotic therapy, and surgical re-insertion of a new medical device at a later date. The discomfort to patients and the high costs of these procedures are evident. [0020]
  • The treatment of biofilm-mediated infection on the surface of medical devices is currently extremely difficult, and no medical device or remedy presently available adequately manages liquid-flow conduit line-related infection. Therefore, there is an urgent need for a method of providing adequate doses of antibiotic consistently in targeted fashion on the surface of in-dwelling medical devices so that bacteria are unable to establish a biofilm during the first five to ten, or more days after insertion of the medical device or application of dressings, suture, pins, clips, and other medical devices. There remains a need to develop a practical method for deterring microbial biofilm development on the surface of catheters and other indwelling medical devices in contact with tissue, so that device-related infections are significantly reduced. [0021]
  • It is an object of the present invention to provide a biocompatible hydrogel matrix, containing liposomal antibiotic that can be coated onto the surface of in-dwelling biomedical devices. It is a further objective to provide methods for formulating such hydrogel matrix compositions; and it is a still further objective to provide methods to co-valently attach said hydrogel to the surface of substrates such as catheters. The type of drug incorporated into the hydrogel formulation is not restricted to any single antibiotic, or combination of one or more of these. Similarly, the hydrogel composition might comprise a variety of active agents including antibiotics, hormones, growth factors and other factors that are beneficial for the condition under management, in accordance with sound medical judgement. [0022]
  • SUMMARY OF THE INVENTION
  • The present invention avails the use of antibiotic-loaded liposomes sequestered within a biocompatible hydrogel retained on the surface of the biomedical device, e.g. catheter. Liposomes, microspheres, nanospheres, biodegradable polymers, and other systems are excellent drug delivery vehicles; and the methods of preparation and drug loading procedures for liposomes and the others are well-known in the art. Liposomes can store both apolar and polar compounds via interactions with the biocompatible and biodegradable lipid bilayer, or compartmentation within the aqueous core, respectively. [0023]
  • A method for producing a biofilm-resistant surface might involve the binding of antibiotic-containing liposomes directly to the surface. Theoretical calculations however, indicate that if a surface was saturated with drug-carrying liposomes, only about 150 ng of the antibiotic ciprofloxacin could be localized per square centimeter of surface. Nanogram quantities of ciprofloxacin are unlikely to provide protection from microbes over substantial periods of time, e.g. several days or more. We have devised a means to effectively exploit the space above the catheter's surface to significantly increase the surface area concentration of bound liposomal antibiotic. Specific formulation of the liposome bilayer allows for drug release over a period ranging from days to weeks. See, e.g., R. Nicholov, V. DiTizio, and F. DiCosmo, “Interaction of paclitaxel with phospholipid bilayers,” [0024] J. Lipo. Res., 5, 503-522 (1995). M. S. Webb, T. O. Harasym, D. Masin, M. B. Bally, and L. D. Mayer, “Sphingomyelin-cholesterol liposomes significantly enhance the pharmokinetic and therapeutic properties of vincristine in murine and human tumour models,” Br. J. Cancer, 72, 896-904 (1995). Furthermore, the biocompatibility of liposomes ensures that they will be safely degraded and assimilated by the host after their supply of drug is exhausted after six days or more.
  • The method of the present invention provides for co-valently attaching liposomes to a substrate such as a catheter, or other liquid-flow conduit, or other device, such as a wound dressing. The method exploits the surface area of the device as well as the volume occupied by the hydrogel matrix bonded to the surface. The volume of gel matrix can accommodate large quantities of drug-loaded liposomes, microspheres, nanospheres, or other drug carrier and consequently, relatively high doses of a therapeutic drug can be deposited at specific sites. The hydrogel matrix is biocompatible and biodegradable (i.e. does not release potentially toxic degradation products), and will ensure protection of the liposomes from membrane-disrupting shear forces that are encountered during handling and insertion of the device, and from rapid degradation of the liposome in vivo. The containment of the liposomes within the gel matrix also creates an opportunity to control drug diffusion rates, thereby affording long-term drug efflux. [0025]
  • Thus, the present invention includes a method for loading efficacious quantities of a liposomal therapeutic agent on a medical device by mixing said liposomal therapeutic agent with a hydrogel, and covalently binding said hydrogel to a pre-formed polymeric surface of a medical device. By pre-formed polymeric surface is meant that the polymeric material used in fabricating the medical device is formed or manufactured in advance of the covalent attachment of the hydrogel. As discussed more fully below, covalent attachment of the hydrogel to the polymeric material can be effected through the use of a bifunctional linker molecule, preferably one comprising an azide functional group. Preferably, the pre-formed polymeric surface is a silicone rubber. [0026]
  • One such embodiment is a silicone catheter loaded with a co-valently bonded polyethylene glycol-gelatin matrix containing a liposomal antibiotic-carrier coating to control catheter-related infections, such as bacteriuria and septicemia. Medical devices where the coating can be used include catheters, wound closures, surgical dressings, temporary orthopedic implants and others. [0027]
  • The liposomal hydrogel of the present invention includes a variety of hydrogel drug combinations. Generally, the selection or pairing of the hydrogel and drug is determined only by the desired application and relevant indication. That is, any active agent that can be compounded into liposomes, microspheres, nanospheres, or other suitable encapsulation vehicle can be confined within the hydrogel matrices of the present invention to create the therapeutic hydrogels of the present invention. Those hydrogels can then be affixed to a substrate such as the surface of a catheter or other in-dwelling liquid conduit, or the substrate or matrix of a wound closure or wound dressing material. [0028]
  • One embodiment of the present invention involves the deposition and co-valent attachment of a polyethylene glycol-gelatin matrix layer to the surface of in-dwelling biomedical implants (e.g. catheters, stents, intravenous tubes, dialysis tubes, orthopedic implants, surgical sponges and wound dressings, etc.) and the sequestration or co-valent attachment of liposomes to the constituents of the matrix. The liposomes contain a therapeutic. The matrix thus constitutes a vehicle for the containment of high concentrations of therapeutic agent such as one or more antibiotics, hormones, steroids, growth factors, antihistamines, colony stimulating factors, interleukins, and the like, and/or combinations thereof. The therapeutic hydrogels of the present invention can be used in the management of tissue and biomaterial associated infection. The matrix can be a hydrogel (e.g., gelatin, pectin, etc.), a protein (e.g. collagen, hemoglobin, etc.), or other adjuvant. Preferably, the matrix will have some structural integrity as by cross-linking or similar structural support to impart resistance to shear forces resulting from insertion of the device. [0029]
  • Thus, the present invention provides a medical device having a polymeric substrate; a matrix material covalently bound to said substrate; and a liposomal therapeutic agent confined within said matrix material. The matrix material can be a hydrogel, a protein, or other suitable adjuvant. The matrix material will preferably be a cross-linked material. One example is gelatin cross-linked with polyethylene glycol as by reacting gelatin with bis-(amine)-PEG. [0030]
  • Matrix material can be covalently bound to a substrate by a variety of means. For example, a protein such as gelatin can be derivatized with a bifunctional linker molecule such as 4-azido-2,3,5,6-tetrafluorobenzoic acid That is, the carbonyl carbon of the benzoic acid group can be made to react with a free amine of a protein to form an amide; the azido functionality can be made to react with a methylene carbon of the silicone rubber. In this manner, the matrix material is covalently bonded to the substrate. [0031]
  • The therapeutic hydrogels of the present invention serve as support material for a variety of liposomal therapeutics. Any therapeutic agent suitable for encapsulation in a liposome, microsphere, nanosphere or the like can be utilized in the present invention. For example, therapeutic agents useful in the present invention include antibiotics, antihistamines, hormones, steroids, therapeutic proteins, and the like. [0032]
  • It will be appreciated by those of ordinary skill in the art that the desired concentration of active agent within a hydrogel loaded on a substrate will vary depending upon the characteristics of the chosen active agent. For example, as between an antibiotic and a therapeutic protein, the required concentration of antibiotic, which are generally active in the microgram range, will likely be higher than the concentration of a therapeutic protein, many of which are active in the nanogram range. Other standard dosing criteria will also be considered in selecting the concentration ranges of active agent loaded onto the substrate in accordance with standard practice in the art. [0033]
  • A preferred embodiment of the present invention is a gelatin hydrogel cross-linked with polyethylene glycol (PEG); and dispersed within the hydrogel is a liposomal antibiotic such as ciprofloxacin. Ciprofloxacin has been shown to exhibit good activity against a broad spectrum of bacteria, particularly those associated with urinary tract infections. [0034]
  • Such embodiments provide dramatically improved in-dwelling medical devices. Medical devices of the present invention can be loaded with as much as 1000 μg/cm[0035] 2 ciprofloxacin. Preferred embodiments have about 10-300 μg/cm2; and still more preferred embodiments have about 25-200 μg/cm2. Thus, the present invention avails long-term, slow release of an anti-infective active agent from an in-dwelling medical device; and dramatically reduces the frequency with which such in-dwelling medical devices must be removed and replaced.
  • The PEG-gelatin-liposome mixture can be effectively applied to the surface of a silicone Foley catheter that has been pre-treated with phenylazido-modified gelatin. Methods for immobilization of photoreactive gelatin on the catheter's surface are presented herein. Use of silicone devices is not a limiting feature, as any such polymeric device can be treated to harbor a hydrogel in which liposomes, or other drug carriers are sequestered. [0036]
  • More specifically, the present invention provides a method for associating substantial quantities of antibiotic-releasing liposomes with a silicone Foley catheter through their inclusion in a surface-coating of PEG-gelatin hydrogel covalently linked to the silicone surface, and the antibiotic was released to the surrounding area over a period of greater than five days. Modifications of the technique should allow it to be applied to other medical devices as well, such as, intraperitoneal catheters, joint and vascular prostheses, and reconstructive implants. An attractive feature of this system is the possibility of sustained release of compounds having a range of chemical properties, such as antibiotics, enzymes, growth factors, human hormones, anticoagulants, etc. Also, the surface characteristics of the PEG-gelatin hydrogel will improve biocompatibility of the device as hydrogel-coated catheters tend to minimize the inflammation associated with the presence of any foreign object in the body. J. N. Nacey and B. Delahunt, “Toxicity study of first and second generation hydrogel-coated latex urinary catheters,” [0037] Br. J. Urol., 67:314-316 (1991). The inclusion of gelatin in our hydrogel system will lead to its eventual degradation in vivo leaving a co-valently-bonded surface layer of AFB-gelatin that should be relatively resistant to further protease digestion. T. Okada and Y. Ikada, “In vitro and in vivo digestion of collagen covalently immobilized onto the silicone surface,” J. Biomed. Mater. Res., 26:1569-1581 (1992). It is possible that the remaining layers of gelatin will facilitate better integration of the catheter with the surrounding tissue.
  • The liposomal matrix materials of the present invention can be used to prevent or treat patients at risk of or suffering from biofilm mediated infection or other forms of infection associated with in-dwelling medical devices, wound closures, and the like. The method comprises inserting into a patient a medical device of the present invention, said medical device comprising a substrate, as for example, a silicone rubber substrate, and covalently bound to said substrate is a hydrogel within which is dispersed a liposomal therapeutic material such as an antibiotic. Likewise, the method comprises replacing infected medical devices with the medical devices of the present invention. [0038]
  • Definitions [0039]
  • By hydrogel or gel is meant any material forming, to various degrees, a jelly-like product when suspended in a solvent, typically water or polar solvents. These gels can be proteins such as collagen or hemoglobin, or more conventional hydrogels such as gelatin, pectin, and fractions and derivatives thereof. [0040]
  • By liposomal therapeutic agents is meant any physical structure surrounding or encapsulating a therapeutic agent such as a drug. Thus, liposomal therapeutic agents will include various drugs or biologically active agents such as antibiotics, antihistamines, hormones, steroids, growth factors, colony stimulating factors, interleukins, and the like confined or encapsulated within a structure such as a liposome, whether of unilamellar or bilayer structure, or microspheres or nanospheres or the like. [0041]
  • A bifunctional linker molecule is any molecule possessed of at least two functional groups that can chemically react with and form covalent bonds with other functional groups or chemical substituents such as the free amines of proteins and the like. Preferably, the bifunctional linker will have an aryl amine functionality, as in an aroyl azide group, and a carbonyl functionality, as in a carboxylic acid group.[0042]
  • DETAILED DESCRIPTION OF THE INVENTION
  • AFB-Gelatin Preparation and Degree of Substitution [0043]
  • NHS-AFB was prepared as described in J. F. W. Keana and S. X. Cai, “New reagents for photoaffinity labeling and photolysis of functionalized perfluorophenyl azides,” [0044] J. Org. Chem., 55:3640-3647 (1990) using the coupling agent DCC. AFB-gelatin of varying degrees of substitution was synthesized by the addition of NHS-AFB in methanol to a solution of gelatin (0.5-1.0%) in 50 mM Borate buffer (pH 8.6). The mixture was incubated overnight at room temperature with stirring. Following filtration through 0.22 μm Millex-GS syringe filters (Millipore, Bedford, Mass.), the solution was dialyzed for 24 hours at 4° C. with three changes of water (pH=4.6 when dialysis complete). The benzoylated gelatin precipitated under these conditions and was collected by centrifugation (10,000×g for 10 minutes). The precipitate was dried in vacuo for 2 hours. All procedures involving AFB were performed in the dark or under dim light conditions.
  • The degree to which gelatin's amino groups reacted with NHS-AFB was determined. In brief, 20 μg of gelatin or AFB-gelatin in 1.5 mL of 50 mM Na[0045] 2PO4 buffer (pH 8.0) was used. While mixing the protein solution using a vortex agitator, 0.5 mL of fluorescamine in dioxane (1.1 mM) was added and mixing continued for 15 seconds. The fluorescence intensity at 475 nm was measured (390 nm excitation wavelength and 8 nm slit widths) and used to calculate the degree of substitution, α, according to the equation α=Fp−Fs/(Fp+0.078·Fs), where Fp =fluorescence of gelatin, Fs=fluorescence of AFB-modified gelatin, and 0.078·Fs represents a correction factor accounting for the increase in molecular weight of gelatin completely substituted with AFB.
  • Determination of the Amount of Gelatin Bound to Silicone Surface [0046]
  • Gelatin was iodinated using Iodo Beads (Pierce, Rockford, Ill.) according to the supplier's directions. In brief, 100 μg of gelatin (500 μL of 0.2 mg/mL gelatin in Hepes buffered saline, pH 7.4 (HBS)) was added to a vial containing 4 Iodo Beads in 2 mL of HBS. Na[0047] 125I (1 mCi from Amersham Canada, Oakville, ON) was added to the reaction vial and left to react for 15 minutes. Transfer of the protein to a second vial terminated the reaction. The reaction vial was washed with three 0.5 mL aliquots (200 μg/mL) of unlabeled gelatin. The protein solution (approx. 400 μg in 2.1 mL of HBS) was dialyzed in 200 mL of buffer until the dialysate was minimally radioactive (approx. 48 hrs with 5 changes of medium).
  • The specific activity of the iodinated gelatin was determined by a technique that exploits the insolubility of the complex formed between gelatin and the dye Sirius Red in acetic acid Four 50 μL aliquots were removed from the iodinated protein solution and added to 1.5 mL polypropylene centrifuge tubes, followed by the addition of 50 μL of HBS and 1 mL of Sirius Red (50 μM) in 0.5 M acetic acid. The tubes were incubated at room temperature for 30 minutes and subsequently centrifuged at 12,000×g for 30 minutes. The supernatant was removed and a portion (0.5 mL) was used for protein quantitation via the decrease in absorbance (540 nm) of the dye remaining in solution. The protein/dye pellet was resuspended with three 150 μL washes of 0.2 N NaOH containing 2 mg/mL gelatin. The radioactivity of the eluate was measured in a liquid scintillation counter. Control experiments indicated that the presence of Sirius Red in the scintillation fluid did not interfere with the determination of [0048] 125I radioactivity. Residual adsorbed protein was measured by cutting the centrifuge tubes into quarters and placing them in scintillation vials for counting. The specific activity was calculated to be 0.12±0.01 μCi/μg. This level of labeling is consistent with the paucity of tyrosine and histidine residues in gelatin.
  • Photoimmobilization Efficiency of AFB-([0049] 125I)gelatin
  • Radioiodinated gelatin was modified with AFB as described above, however, the coupling solution and dialysis medium consisted of HBS (pH 8.0 and 7.4, respectively). The ratio of NHS-AFB to gelatin in the coupling solution was 1:4 (w/w). Following dialysis, the volume of the AFB-([0050] 125I)gelatin solution was made up to 5 mL and the protein concentration was determined to be 3.9±0.6 ng/μL. Aliquots (10 μL each) of radioiodinated AFB-gelatin were applied to the side of silicone rectangles corresponding to the outer surface of the original catheter. All sections (12 in total) were dried under vacuum for 90 minutes. One set of four catheter pieces were then immediately placed in scintillation fluid (exterior surface facing up) for counting. Another set was exposed to short wave (254 nm) UV light (Minerallight Lamp, UVP, San Gabriel, Calif.) at a distance of 2 cm for 3 minutes. This set of four sections plus the remaining four sections were subsequently washed in 1% SDS solution at 80° C. for 30 minutes with a change of medium after 15 minutes. The sections were rinsed in distilled water and placed in scintillation vials for counting.
  • Liposome and PEG-gelatin Gel Preparation [0051]
  • Liposomes were composed of DPPC/Cholesterol/PEG-DSPE/Rhodamine-DPPE in a 1:1:0.05:0.001 ratio. The formulation to be used is not limiting, and any number of lipid-to-other-constituents ratios may be used to effectively achieve the embodiments of this invention. The lipids were dissolved in 4 mL of chloroform and the solvent was removed in vacuo. The resulting lipid film was placed under vacuum for two hours and subsequently hydrated with 1 mL of 250 mM ammonium sulfate (pH 2.5) at 45° C. Liposomes were then frozen in liquid nitrogen and thawed in a 45° C. water bath (5X), followed by high-pressure extrusion through two 100 nm-pore membranes (10X). This procedure has been shown to produce unilamellar liposomes with an average diameter of 100 nm and an equal solute distribution between the exterior and interior of the liposomal membrane. M. J. Hope, M. B. Bally, G. Webb, and P. R. Cullis, “Production of large unilamellar vesicles by a rapid extrusion procedure. Characterization of size distribution, trapped volume and ability to maintain a membrane potential,” [0052] Biochim. Biophys. Acta, 812:55-65 (1985); L. D. Mayer, M. J. Hope, P. R. Cullis, and A. S. Janoff, “Solute distributions and trapping efficiencies observed in freeze-thawed multilamellar vesicles,” Biochim. Biophys. Acta, 817:193-196 (1986). External ammonium sulfate was removed by passing the suspension through a G-50 column (1×10 cm) and eluting with a 10% sucrose solution (pH 4.0).
  • PEG-gelatin solutions consisted of 10% gelatin, 6% NP-PEG and 10% sucrose at pH 4.0. If liposomes were required, they were added from a pure liposome suspension. The concentration of liposomes in PEG-gelatin solutions was 15 mM with respect to DPPC. All solutions were heated at 45° C. for 15 min. to dissolve gelatin. [0053]
  • Crosslinking the Gelatin Matrix [0054]
  • The PEG-gelatin matrix was also crosslinked by the formation of amide bonds between bis-(amine)-PEG and the free carboxyl groups of gelatin. In this method, the silicone catheter surface is immersed in a solution of aqueous soluble carbodiimide (2 mg/mL) and incubated at room temperature for 30 min. The reaction of the activated carboxyl groups with PEG and gelatin amino moieties is initiated by submersing the silicone material in borate buffer (200 mM, pH 8.5). Incubation in the alkaline buffer proceeds for 2 hr. Subsequently, the silicone surface is placed in 10% sucrose solution for 6 hr, with three changes of medium, to remove non-crosslinked material. This treatment results in a crosslinked PEG-gelatin gel that retains its integrity and remains affixed to the catheter for at least seven days when placed in a 37° C. solution of 10% sucrose. The crosslinking chemistry is outlined in FIG. 4. [0055]
  • Preparation of Catheter Sections [0056]
  • In the preferred embodiment of the invention catheter material that is to be coated with PEG-gelatin gel is first spin-coated with 10 μL of AFB-gelatin (5 mg/mL; α=55%) and dried under vacuum for 1 hour. All sections, including untreated controls, were exposed to UV light (254 nm) for 3 minutes and rinsed with water. Subsequently, catheter pieces are spin-coated with 60 μL of fluid PEG-Gelatin or PEG-gelatin-liposome mixture and incubated at 4° C. for 15 minutes. Incubation may occur at temperatures from 4-10°[0057] 0 C. Gels were polymerized by submersing catheter sections in 200 mM Borate buffer (pH 8.5) for 1 hr. Residual p-nitrophenol was leached from the gels by incubation at room temperature in 10% sucrose (pH 4.0) for 12 hrs, with four changes of medium. The absence of p-nitrophenol was confirmed by negligible absorbance of the dialysate at 410 nm.
  • Liposomes in suspension and those entrapped within PEG-gelatin gels were loaded with ciprofloxacin (Bayer, Leverkusen, Germany) according to the remote-loading technique described in Y. K. Oh, D. E. Nix, and R. M. Straubinger, “Formulation and efficacy of liposome-encapsulated antibiotics for therapy of intracellular [0058] Mycobacterium avium infection,” Antimicrob. Agents Chemother., 39:2104-2111 (1995). Catheter pieces were placed in 10% sucrose solution (pH 7.5) containing 2 mM ciprofloxacin, while for liposomes in suspension, an appropriate amount of drug was added to make the suspension 2 mM in ciprofloxacin. Incubation in both cases proceeded for 1 hour at 45° C. The liposome suspension was centrifuged at 3000×g for 5 minutes to pellet drug crystals and the supernatant was then applied to a G-50 column (1×10 cm) to remove unentrapped ciprofloxacin.
  • Dehydrated hydrogels were prepared by drying coated catheter sections in an oven at 35° C. for 2.5 hr. The dried gels were then rehydrated in Tris buffer (10 mM Tris, 110 mM NaCl, pH 7.4) or in concentrated ciprofloxacin-HCl solution (25 mg/mL) as required. The temperature during the rehydration process was maintained at 45° C. [0059]
    TABLE I
    Ciprofloxacin Loading into Liposomes and PEG-Gelatin Gel
    Sample Total Ciprofloxacin Entrapped
    PEG-Gelatin Gela  42 ± 12 μg/cm2
    PEG-Gelatin-liposome Gela 185 ± 16 μg/cm2
    PEG-Gelatin-Liposome Gelb 3083 ± 267 μg/cm3
    Dry PEG-Gelatin-Liposome Gela 173 ± 6 μg/cm2 
    Dry PEG-Gelatin Gela,c 1253 ± 80 μg/cm2 
    Dry PEG-Gelatin-Liposome Gela,c 1298 ± μg/cm2    
    Liposomes-only 0.52 ± 0.04 μmol cipro/μmol lipid
  • The quantity of therapeutic agent loaded on the substrate can be increased or decreased over greater ranges than those shown in Table I. Greater concentrations of therapeutic agent can be loaded by increasing the amount of drug encapsulated and mixed into the hydrogel. For example, we expect that concentrations up to about 1,000 μg (1.0 mg) per cm[0060] 2 or more of an antibiotic active agent can be loaded on substrates with the methods of the present invention; and that concentrations of up to about 10,000 μg/cm3 or more can be loaded on substrates. A preferred concentration range of antibiotic loaded on such substrates is about 10-1,000 μg/cm2. A preferred range for ciprofloxacin is about 10-200 μg/cm2.
  • Similarly, quantities of therapeutic agent can be increased by increasing the quantity of gel immobilized on the surface of the substrate. Generally, hydrogel layers of about 0.5-10 mm thick can be loaded on substrates to effect the desired drug delivery and therapeutic results; preferred layers are in the range of about 1-5 mm; and especially preferred layers are about 2-4 mm. [0061]
  • Thus, one of skill in the art will appreciate that the present methods and devices afford highly versatile means for loading high concentrations of anti-infective agents, and of varying the concentration of such agents, on a substrate or on a specific area of a substrate. [0062]
  • Determination of Drug Efflux Kinetics [0063]
  • The release experiment was initiated by placing each catheter section or dialysis membrane (containing liposome suspension 2.7 mM in DPPC) into separate liquid scintillation vials filled with 15 mL of Tris buffer. At selected [0064] time intervals 3 mL was removed from each vial for ciprofloxacin quantitation via a fluorescence-based assay using an excitation wavelength of 324 nm, an emission wavelength of 450 nm, and 5 nm slit widths. The amount of ciprofloxacin present was determined by comparisons to a standard curve. The remaining solution in the vials was emptied and replaced with 15 mL of buffer. The samples were incubated at 37° C. throughout the experiment.
  • Bacterial Biofilm Formation Assay [0065]
  • A clinical isolate of [0066] Pseudomonas aeruginosa obtained from a patient with peritonitis was used for all challenge assays. An 18 h nutrient broth culture was prepared from a primary isolate maintained at -−70° C. in a 50% (v/v) glycerol-phosphate buffered saline (PBS) solution.
  • Catheter sections were aseptically placed in 100 mL of sterile nutrient broth (Difco, Detroit, Mich.) contained within a 250 mL glass beaker. Twelve catheter sections from each coating formulation were added to individual beakers. The [0067] P. aeruginosa culture was washed 3 times in a pH 7.1 PBS solution, then inoculated to each of the beakers. The inoculum size was sufficient to yield 1.5±0.5×107 cfu/mL in the 100 mL volume. The inoculated catheter suspensions were then placed in an incubator maintained at 37° C. and agitated at a rate of 100 rpm. One half of the 100 mL volume was aseptically removed from each beaker and replaced with a like volume of sterile nutrient broth on a daily basis. At time intervals of 1, 3, 5, and 7 days, triplicate catheter sections were removed from each of the beakers and viable bacteria were recovered from the catheter surfaces as described below. The number of viable bacteria in nutrient broth samples was also determined.
  • The catheter sections were removed from the bacterial suspensions and individually rinsed with a 10 mL volume of sterile PBS delivered via a gravity feed from a 10 mL pipet. The rinsed sections were placed in 20 mL plastic test tubes containing 5 mL volumes of sterile PBS and 3 mm diameter glass beads. Following sonication for 30 s in an ice cold sonicator bath (Bransonic, Danbury, Conn.), the catheter sections were vortexed for 1 minute at high speed. The sonication and vortexing procedure was repeated three times. Aliquots were then removed from each of the suspensions and plated to nutrient agar. The plates were incubated at 37° C. for 48 h. [0068]
  • Degree of Substitution of AFB-gelatin [0069]
  • The modification of the silicone catheter surface in this example used the photoreactive molecule 4-azido-2,3,5,6-tetrafluorobenzoic acid (AFB). It can be linked to the amino groups of gelatin via N-hydroxysuccinimide (NHS) chemistry. Based on the amino acid composition of ox hide gelatin, (J. E. Eastoe and A. A. Leach, “Chemical constitution of gelatin,” in [0070] Science and Technology of Gelatin, A. G. Ward and A. Courts (eds.), Academic Press, New York, 1977, pp. 73-107) the typical gelatin molecule (MW 75,000) contains approximately 25 ε-amino groups derived from lysine and hydroxylysine. The reactivity of these groups towards NHS-AFB was determined by varying the ratio of gelatin to NHS-AFB. Table 1 shows that a 1:9 ratio of ε-amino groups to NHS-AFB leads to nearly complete (99%) substitution of available amino groups. A 1:0.75 ratio results in approximately 55% substitution. Fifty-five percent substitution represents the optimal value for the modification of gelatin with AFB because it allows for both binding to the surface via the azide moiety and attachment to the PEG-gelatin coating through linkage to the carbonate group of NP-PEG. However, lower or higher substitutions can be used to achieve a desired effect.
  • Binding of AFB-gelatin to Silicone [0071]
  • The high reactivity of aryl azides has been exploited in biochemistry for some time via the use of photoaffinity ligands. Such azides typically yield poor carbon-hydrogen (C-H) insertion efficiencies due to competing side reactions exemplified by ring expansion. A. K. Shrock and G. B. Schuster, “Photochemistry of phenyl azide: chemical properties of the transient intermediates,” [0072] J. Am. Chem. Soc., 106:5228-(1984). Fluorination of the benzene ring promotes excited state stability and results in improved insertion efficiencies. E. Leyva, M. J. T. Young, and M. S. Platz, “High yields of formal CH insertion products in the reactions of polyfluorinated aromatic nitrenes,” J. Am. Chem. Soc., 108:8307 (1986). The fluorinated aryl azide (AFB) used for the present invention has been shown to be capable of binding to various atoms in usually inert chemical groups such as the carbon in methyl groups. A possible reaction scheme for AFB-gelatin linkage to polydimethylsiloxane (PDMS) via C-H insertion is depicted in FIG. 1B.
  • To date no data has been published regarding the ability of AFB to insert into a PDMS-based (silicone rubber) network. [0073]
  • In order to verify that AFB-gelatin covalently attaches to the surface of a silicone catheter, a small volume of a dilute solution of radioiodinated AFB-gelatin was placed onto sections of catheter, dried under vacuum, exposed to UV light, and vigorously washed in detergent solution at high temperature. The radioactivity measured in samples exposed to UV light minus the radioactivity detected in the unexposed samples was taken as a measure of the amount of gelatin that was covalently bound to the silicone. It was found that UV irradiated samples bound approximately 32 times more AFB-gelatin than did unirradiated samples (approximately 5.1 ng versus 0.16 ng). An estimation of the binding efficiency was obtained from division of the radioactivity detected in UV exposed samples by the radioactivity measured in samples that had been placed in scintillation fluid immediately after the initial drying step. The binding efficiency was measured as 27±5%. This value is an approximately upper limit since the AFB-gelatin used had an α value of 93%. The data suggest that AFB-gelatin forms covalent links to the silicone catheter's surface. [0074]
  • Ciprofloxacin Efflux Studies [0075]
  • Ciprofloxacin release rates were determined for the following samples: liposomes-only, PEG-gelatin hydrogel alone, a liposomal PEG-gelatin hydrogel, and a drug-containing liposomal hydrogel that was air dried and then rehydrated with pH 7.4 Tris buffer. All the liposomes used in this study contained DPPC and cholesterol. PEG-lipid was also included to avoid gelatin-induced destabilization of the bilayer and to increase immobilization of the liposomes within the hydrogel matrix via stearic interactions. The results of the experiment are summarized in FIG. 2. The quantity of ciprofloxacin released at a given time point is expressed as a percentage of the total amount released throughout the experiment. There are two notable trends. The hydrogel-only, and rehydrated liposomal hydrogel treatments were not successful in retaining ciprofloxacin for a sustained period of time; almost all of the drug initially incorporated was released within the first two hours. [0076]
  • Surprisingly, it took longer than 6.8 days (or 163 hrs) for greater than 99% of the initially incorporated drug to be released from liposomes and the liposomal hydrogel that was not dehydrated. The similarity in results for the latter two treatments indicates that hydrogel-embedded liposomes maintain their integrity during the coating procedure and throughout the experimental period. It should be noted that all hydrogels remained affixed to the catheter surface for at least seven days. This is a practical solution in delivering antibiotic or other drug to the site of infection or other tissue area in need of treatment, respectively, for a time greater than five or more days. [0077]
  • Also, the presence of rhodamine-DPPE in the membrane of liposomes endowed liposomal hydrogels with a pink color that did not noticeably decrease in intensity throughout the course of the experiment indicating that the liposomes remained embedded within the hydrogel and did not shift from the intended locations. [0078]
  • The dried liposomal hydrogel, i.e., dried prior to being loaded with antibiotic, was found to maintain its sustained release properties after rehydration and is an important consideration for the clinical application of the system. An effective drying and rehydration process uses the dried liposomal hydrogel rehydrated in a solution containing 25 mg of ciprofloxacin. As a control, a dried hydrogel containing no liposomes was hydrated in a 25 mg/mL ciprofloxacin solution. The total average amount of antibiotic entrapped within these hydrogels is listed in Table 2, and for comparative purposes the total entrapped drug is also included. The hydrogels rehydrated in concentrated ciprofloxacin solution (25 mg/mL) retained very large quantities of antibiotic (approx. 1.4 mg/ 1 cm catheter section). Almost all (>99%) of the hydrogel-associated ciprofloxacin was released after the first four hours of incubation, as expected from an analysis of the prior art. [0079]
  • The release kinetics of ciprofloxacin from selected hydrogel treatments can be followed by analyzing the data in Table 3. Despite the large initial release of antibiotic, it is evident that there was still a small, but continual release of ciprofloxacin from the dried liposomal hydrogels rehydrated in concentrated ciprofloxacin solution. In comparison, the release of ciprofloxacin from the dried hydrogel-only treatment was negligible from 20.5 hours and onwards. [0080]
  • Ciprofloxacin was incorporated into dried liposomal hydrogels during the rehydration step since our data indicated that pre-loaded liposomes embedded in a hydrogel were destabilized by dehydration. In effect, antibiotic was encapsulated within liposomes as they reformed during the rehydration of the PEG-gelatin film. Our calculations indicate that the encapsulation efficiency of ciprofloxacin in liposomes generated in situ was 7% relative to the amount of ciprofloxacin in pre-formed liposomes. The variation can be accounted for by the different loading techniques used. In general, compounds are more efficiently concentrated within liposomes when using a remote-loading technique exploiting pH and ammonium sulfate gradients than when a lipid film hydration method is employed. [0081]
  • The optimal efflux profile in terms of prolonged release of substantial antibiotic quantities was obtained from liposomal hydrogel samples that were not dehydrated. The hydrogel system was shown to be capable of releasing substantial quantities of drug for up to 7 days. It is possible to improve the amount and duration of release by increasing the concentration of liposomes within the hydrogel; this aspect is not limiting. For example, the concentration can be at least doubled without affecting hydrogel stability. Increasing the liposome concentration allows the air dried liposomal hydrogel system to become a viable alternative as this compensates for the decrease in drug encapsulation efficiency associated with the in situ generation of liposomes. Alternatively, a dried liposomal hydrogel with suitable sustained release properties as presented here may be obtained by the development of a lyophilization protocol. Numerous studies have shown that liposomes freeze-dried in the presence of sugars such as sucrose or trehalose can be rehydrated without substantial loss of their contents. L. M. Crowe, J. H. Crowe, A. Rudolph, C. Womersley, and L. Appel, “Preservation of freeze-dried liposomes by trehalose,” [0082] Arch Biochem. Biophys., 242:240-247 (1985); W. Q. Sun, A. C. Leopold, L. M. Crowe, J. H. Crowe, “Stability of dry liposomes in sugar glasses,” Biophys. J., 70:1769-1776 (1996).
  • Bacterial Biofilm Formation Assay [0083]
  • A practical aim of this invention is toward a catheter, or any polymeric biomedical device coating capable of resisting colonization by bacteria and subsequent infection in vivo and during application. To this end, untreated, PEG-gelatin coated, and ciprofloxacin-containing liposomal hydrogel catheter sections were challenged with a clinical strain of [0084] P. aeruginosa known to form biofilms on silicone catheters. The hydrogel coating containing antibiotic liposomes was effective in preventing cells from adhering and remaining viable. The number of viable bacteria in the broth containing these sections was approximately 6.7×102 cfu/mL at the end of the experiment. This suggests that the absence of viable cells on the catheter surface was not simply due to the total elimination of the initial inoculum resulting from the release of drug during the first few hours. It is likely that the continual release of ciprofloxacin for a time greater than five days significantly contributed to the nearly complete prevention of adhesion of viable bacteria and elimination of the potential biofilm. Another contributing factor may have been the presence of PEG in the hydrogel. Previous studies have shown that polymers coated with polyoxyethylene chains can prevent or retard bacterial cell adhesion. Fewer bacteria were able to adhere to catheter sections coated with PEG-gelatin gel relative to untreated samples. The approximately two order of magnitude decrease in bacterial cell adhesion may be further improved by increasing the concentration of PEG in the hydrogel.
  • General [0085]
  • The phospholipids dipalmitoylphosphatidylcholine (DPPC) and PEG-distearoylphosphatidylethanolamine (PEG-DSPE) were obtained from Avanti Polar Lipids (Alabaster, Ala.). Rhodamine dipalmitoylphosphatidylethanolamine (rhodamine-DPPE) and 4-azido-2,3,5,6-tetrafluorobenzoic acid (AFB) were purchased from Molecular Probes (Eugene, Oreg.). Porcine gelatin-a (MW 50,000-100,000), polyoxyethylene bis(p-nitrophenyl carbonate) (NP-PEG), and cholesterol were obtained from Sigma (St. Louis, Mo.). Fluorescamine, 1,3-dicyclohexylcarbodiimide (DCC), N-hydroxysuccinimide (NHS), and Sirius Red were purchased from Aldrich (Milwaukee, Wis.). All reagents and solvents were of analytical grade and were used without further purification. Deionized water (Milli-Q, Millipore, Bedford, Mass.) filtered through a 0.22 μm membrane was used in all experiments. Ciprofloxacin (Bayer, Germany) was analyzed in a Perkin Elmer LS-50 fluorimeter. Sirius Red and p-nitrophenol were quantitated using a Hewlett-Packard 8450 spectrophotometer. [0086]
  • Silicone Foley catheters (Sherwood Medical, St. Louis, Mo.) were prepared for use by sectioning into cylinders (3 mm diameter and 10 mm length). The open ends of the sections were sealed with silicone rubber (RTV 108, GE, Pickering, ON). Occasionally, cylindrical sections were further subdivided into rectangular pieces (5 mm×3 mm). Silicone sections were cleaned prior to each experiment by refluxing in methanol for six hours. [0087]
  • Two pediatric silicone Foley catheters were coated with a PEG-gelatin-liposome composition of the present invention as described herein, under aseptic conditions. The catheters were inserted into the urethra of two male New Zealand white rabbits. After ten minutes the catheters were removed; and the catheters and excised urethra were examined. No disruption of the gel was observed on the catheter, and no gel fragments were detected in the urethra. [0088]
  • Table 2. The degree of substitution of gelatin with AFB as a function of the initial ratio of ε-amino groups to NHS-AFB. [0089]
    ε-NH2/NHS-AFB Degree of Substitution (%)
    9 99 ± 4
    2 93 ± 4
    1 71 ± 5
    0.75 −55 ± 2  
  • Table 3. Release of ciprofloxacin from liposomes alone, constantly hydrated liposomal PEG-Gelatin hydrogel (LipoGel), dried liposomal PEG-Gelatin gel rehydrated 25 mg/mL ciprofloxacin solution (DryLipoGel (25 mg)), and dried PEG-Gelatin gel rehydrated in 25 mg/mL ciprofloxacin solution (DryGel (25 mg)). [0090]
    CIPROFLOXACIN RELEASED
    (μg/15 mL)
    TIME DryLipoGel DryGel
    (Hours) Liposomes LipoGel (25 mg) (25 mg)
    2.0 6.1 ± 2.1 39.5 ± 9.2 1367 ± 52  1329 ± 86 
    4.0 3.0 ± 0.4  7.3 ± 2.1 22.5 ± 4.8  22.0 ± 1.9 
    7.5 3.3 ± 0.5  7.2 ± 1.0 3.8 ± 0.9 1.2 ± 0.3
    20.5 10.1 ± 0.6  21.6 ± 2.1 3.5 ± 0.3 0.34 ± 0.11
    53.5 23.2 ± 4.0  67.7 ± 5.7 2.5 ± 0.2 0.14 ± 0.02
    93.5 14.8 ± 4.1  47.7 ± 2.4 1.4 ± 0.2 0.13 ± 0.04
    163.0 5.6 ± 0.9  7.4 ± 0.5 1.1 ± 0.1 0.15 ± 0.09

Claims (42)

What is claimed is:
1. A medical device comprising:
a. a polymeric substrate;
b. a hydrogel matrix material covalently bound to said substrate; and
c. a liposomal therapeutic agent confined within said matrix material.
2. The medical device of claim 1, wherein the hydrogel matrix material is a polyethylene glycol-protein matrix.
3. The medical device of claim 1, wherein the polymeric substrate is silicone rubber.
4. The medical device of claim 3, wherein the silicone rubber comprises polydimethylsiloxane.
5. The medical device of claim 3, wherein the hydrogel matrix material is a polyethylene glycol-gelatin matrix.
6. The medical device of claim 5, comprising a bifunctional linker molecule situated between said silicone rubber substrate and said polyethylene glycol-gelatin matrix material.
7. The medical device of claim 5, wherein said linker molecule is a 4-amino-2,3,5,6-tetrafluorobenzoyl radical.
8. The medical device of claim 1, wherein the liposomal therapeutic agent is selected from among the group consisting of: antibiotics, antihistamines, anti-inflammatories, hormones, steroids, growth factors, colony stimulating factors, interleukins, and combinations thereof.
9. The medical device of claim 1, wherein the liposomal therapeutic agent is an antibiotic.
10. The medical device of claim 1, wherein the liposomal therapeutic agent is a fluoroquinolone antibiotic.
11. The medical device of claim 10, wherein the fluoroquinolone antibiotic is selected from the group consisting of: ciprofloxacin, norfloxacin, ofloxacin, pefloxacin, enoxacin, rosoxacin, amifioxacin, fleroxacin, temafloxacin, and lomefloxacin.
12. The medical device of claim 10, wherein the fluoroquinolone is ciprofloxacin.
13. The medical device of claim 1, wherein the liposomes are formed of a material selected from the group consisting of dipalmitoylphosphatidylcholine and polyethyleneglycol-distearoylphosphatidylethanolamine.
14. A medical device comprising:
a. a silicone rubber substrate;
b. a fluorinated aroyl amine group covalently bound to said substrate;
c. a polyethylene glycol-gelatin matrix material covalently bound to said fluorinated aroyl amine; and
d. liposomal ciprofloxacin dispersed throughout said matrix material.
15. A medical device comprising a silicone rubber substrate covalently binding a therapeutic hydrogel such that the surface of the device is loaded with about 10-1,000 μg active agent per cm2 of substrate.
16. The medical device of claim 15, wherein the active agent is ciprofloxacin.
17. A medical device comprising a silicone rubber substrate covalently binding a therapeutic hydrogel such that the surface of the device is loaded with about 50-200 μg ciprofloxacin per cm2 of substrate.
18. A therapeutic hydrogel composition comprising a liposomal therapeutic agent dispersed throughout a hydrogel.
19. The therapeutic hydrogel of claim 17, wherein the hydrogel contains about 100-10,000 μg of the liposomal therapeutic agent per cm3 of hydrogel.
20. The therapeutic hydrogel of claim 19, wherein the liposomal therapeutic agent is ciprofloxacin.
21. The therapeutic hydrogel of claim 17, wherein the hydrogel is a polyethylene glycol-gelatin hydrogel.
22. The therapeutic hydrogel of claim 17, wherein the liposomal therapeutic agent is a fluoroquinolone antibiotic.
23. A therapeutic hydrogel composition comprising liposomal ciprofloxacin dispersed throughout a polyethylene glycol-gelatin hydrogel.
24. The therapeutic hydrogel composition of claim 23, wherein said gelatin hydrogel is derivatized with 4-azido-2,3,5,6-tetrafluorobenzoic acid or a derivative thereof.
25. A method for loading a liposomal therapeutic agent on a medical device by mixing said liposomal therapeutic agent with a hydrogel, and covalently binding said hydrogel to a pre-formed polymeric surface of a medical device.
26. The method of claim 25, wherein the polymeric surface is a silicone rubber.
27. The method of claim 25, wherein the liposomal therapeutic agent is an antibiotic.
28. A method for covalently attaching a therapeutic hydrogel to a polymeric substrate comprising:
a. derivatizing the hydrogel by covalently binding a protein within the hydrogel to a functional group of a bifunctional linker molecule; and
b. covalently attaching the remaining functional group of the bifunctional linker molecule to the substrate.
29. The method of claim 28, wherein the hydrogel comprises gelatin.
30. The method of claim 28, wherein the bifunctional linker molecule is a fluorinated aroyl azide.
31. The method of claim 30, wherein the bifunctional liner molecule further comprises a carbonyl moiety.
32. The method of claim 28, wherein the bifunctional linker molecule is 4-azido-2,3,5,6-tetrafluoro benzoic acid or a derivative thereof.
33. The method of claim 31, wherein said polymeric substrate is silicone rubber.
34. A method for covalently attaching a therapeutic gelatin hydrogel to a silicone rubber substrate comprising:
a. derivatizing the gelatin of a therapeutic gelatin hydrogel by forming an amide linkage from free amino groups of the gelatin and a carbonyl carbon of a fluorinated aroyl azide; and
b. covalently binding an aryl nitrogen of the azide group of the fluorinated aroyl azide to the silicone rubber substrate.
35. The method of claim 34, wherein the step of binding the azide moiety to the silicone rubber substrate is effected by exposure of the reactants to U.V. light.
36. A method for the prophylaxis or treatment of patients at risk of or suffering from biofilm mediated infection associated with the use of a medical device comprising inserting or applying a medical device formed of a polymeric substrate covalently binding a therapeutic hydrogel matrix.
37. The method of claim 36, wherein said therapeutic hydrogel matrix comprises a liposomal fluoroquinolone antibiotic dispersed throughout said matrix.
38. The method of claim 37, wherein said fluoroquinolone antibiotic is ciprofloxacin.
39. The method of claim 36, wherein said polymeric substrate is a silicone rubber.
40. The method of claim 36, wherein said hydrogel is a polyethylene glycol-gelatin matrix.
41. A method for the prophylaxis or treatment of patients at risk of or suffering from biofilm mediated infection associated with the use of an in-dwelling medical device comprising inserting a medical device formed of a silicone rubber substrate covalently binding a polyethylene glycol-gelatin matrix material, and wherein dispersed within said matrix material is a liposomal fluoroquinolone antibiotic.
42. The method of claim 41, wherein said fluoroquinolone is ciprofloxacin.
US09/849,481 1996-04-12 2001-05-07 Drug delivery via therapeutic hydrogels Abandoned US20020051812A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US09/849,481 US20020051812A1 (en) 1996-04-12 2001-05-07 Drug delivery via therapeutic hydrogels

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US63132696A 1996-04-12 1996-04-12
US08/843,342 US6132765A (en) 1996-04-12 1997-04-15 Drug delivery via therapeutic hydrogels
US09/412,584 US6228393B1 (en) 1996-04-12 1999-10-05 Drug delivery via therapeutic hydrogels
US09/849,481 US20020051812A1 (en) 1996-04-12 2001-05-07 Drug delivery via therapeutic hydrogels

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US09/412,584 Division US6228393B1 (en) 1996-04-12 1999-10-05 Drug delivery via therapeutic hydrogels

Publications (1)

Publication Number Publication Date
US20020051812A1 true US20020051812A1 (en) 2002-05-02

Family

ID=25289698

Family Applications (4)

Application Number Title Priority Date Filing Date
US08/843,342 Expired - Fee Related US6132765A (en) 1996-04-12 1997-04-15 Drug delivery via therapeutic hydrogels
US09/412,584 Expired - Fee Related US6228393B1 (en) 1996-04-12 1999-10-05 Drug delivery via therapeutic hydrogels
US09/818,649 Expired - Fee Related US6475516B2 (en) 1996-04-12 2001-03-28 Drug delivery via therapeutic hydrogels
US09/849,481 Abandoned US20020051812A1 (en) 1996-04-12 2001-05-07 Drug delivery via therapeutic hydrogels

Family Applications Before (3)

Application Number Title Priority Date Filing Date
US08/843,342 Expired - Fee Related US6132765A (en) 1996-04-12 1997-04-15 Drug delivery via therapeutic hydrogels
US09/412,584 Expired - Fee Related US6228393B1 (en) 1996-04-12 1999-10-05 Drug delivery via therapeutic hydrogels
US09/818,649 Expired - Fee Related US6475516B2 (en) 1996-04-12 2001-03-28 Drug delivery via therapeutic hydrogels

Country Status (8)

Country Link
US (4) US6132765A (en)
EP (1) EP0984798B1 (en)
JP (1) JP2001523124A (en)
AT (1) ATE305803T1 (en)
AU (1) AU736584B2 (en)
CA (2) CA2634700A1 (en)
DE (1) DE69831802T2 (en)
WO (1) WO1998046287A2 (en)

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060263323A1 (en) * 2003-03-24 2006-11-23 Becton, Dickinson And Company Invisible antimicrobial glove and hand antiseptic
US20080044553A1 (en) * 2006-08-15 2008-02-21 Abigail Freeman Sterilization methods for medical devices
US20120093914A1 (en) * 2008-11-24 2012-04-19 Moma Therapeutics Implantable liposome embedded matrix composition, uses thereof, and polycaprolactone particles as scaffolds for tissue regeneration
US8709473B1 (en) * 2009-01-28 2014-04-29 Abbott Cardiovascular Systems Inc. Method of targeting hydrophobic drugs to vascular lesions
US20140127287A1 (en) * 2011-05-11 2014-05-08 Wisconsin Alumni Research Foundation (Warf) Liposome-encapsulated hydrogels for use in a drug delivery system
US9364588B2 (en) 2014-02-04 2016-06-14 Abbott Cardiovascular Systems Inc. Drug delivery scaffold or stent with a novolimus and lactide based coating such that novolimus has a minimum amount of bonding to the coating
EP3322365A4 (en) * 2015-05-22 2019-04-17 Orthobond, Inc. Methods, compositions and techniques for polydimethylsiloxane surface modifications
US10314935B2 (en) 2009-01-07 2019-06-11 Entrotech Life Sciences, Inc. Chlorhexidine-containing antimicrobial laminates
US11039615B2 (en) 2014-04-18 2021-06-22 Entrotech Life Sciences, Inc. Methods of processing chlorhexidine-containing polymerizable compositions and antimicrobial articles formed thereby

Families Citing this family (221)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6495579B1 (en) 1996-12-02 2002-12-17 Angiotech Pharmaceuticals, Inc. Method for treating multiple sclerosis
AU3212199A (en) * 1998-03-31 1999-10-18 Scimed Life Systems, Inc. Temperature controlled solute delivery system
US8177762B2 (en) 1998-12-07 2012-05-15 C. R. Bard, Inc. Septum including at least one identifiable feature, access ports including same, and related methods
US7250253B1 (en) * 1999-01-25 2007-07-31 Micronas Gmbh Immobilization of molecules on surfaces via polymer brushes
US7892532B2 (en) * 1999-04-30 2011-02-22 Warsaw Orthopedic, In Emory University Intracellular delivery of osteoinductive proteins and peptides
EP1210046A4 (en) * 1999-06-22 2007-05-02 Res Dev Foundation Enhanced wound coverage to enhance wound healing
CA2345779A1 (en) * 1999-08-27 2001-03-08 Department Of National Defence Hydrogel wound dressing containing liposome-encapsulated therapeutic agent
US6738661B1 (en) * 1999-10-22 2004-05-18 Biosynergetics, Inc. Apparatus and methods for the controllable modification of compound concentration in a tube
WO2001066167A2 (en) * 2000-03-03 2001-09-13 Chuter Timothy A M Large vessel stents and occluders
US6613082B2 (en) * 2000-03-13 2003-09-02 Jun Yang Stent having cover with drug delivery capability
US6800298B1 (en) * 2000-05-11 2004-10-05 Clemson University Biological lubricant composition and method of applying lubricant composition
DE10025803A1 (en) * 2000-05-24 2001-12-20 Jms Co Ltd Polymer surface with biologically active properties and process for their production
US20040018228A1 (en) * 2000-11-06 2004-01-29 Afmedica, Inc. Compositions and methods for reducing scar tissue formation
EP1352072A4 (en) * 2001-01-17 2004-09-01 Zycos Inc Nucleic acid delivery formulations
US20060089721A1 (en) * 2001-01-17 2006-04-27 Muhanna Nabil L Intervertebral disc prosthesis and methods of implantation
EP1359952A1 (en) * 2001-02-07 2003-11-12 EFMT Entwicklungs- und Forschungszentrum Für Mikrotherapie GmbH Dynamic implant coatings
NZ540000A (en) * 2001-02-16 2007-05-31 Abbott Lab Vascular Entpr Ltd Implants with tacrolimus
US20110212152A1 (en) * 2001-02-28 2011-09-01 Ditizio Valerio Modified anti-microbial surfaces, devices and methods
DE60201889T2 (en) 2001-02-28 2006-04-06 Covalon Technologies Inc., , Mississauga METHOD FOR PRODUCING ANTIMICROBIAL POLYMER SURFACES
WO2002072011A2 (en) * 2001-03-08 2002-09-19 Targesome, Inc. Stabilized therapeutic and imaging agents
DE10113108B4 (en) * 2001-03-15 2007-07-26 Dot Gmbh Active substance-containing calcium phosphate materials
US20050276858A1 (en) * 2001-04-23 2005-12-15 Kao Weiyuan J Bifunctional-modified hydrogels
US7615593B2 (en) * 2001-04-23 2009-11-10 Wisconsin Alumni Research Foundation Bifunctional-modified hydrogels
DE50103887D1 (en) * 2001-07-20 2004-11-04 Peter Hildebrandt Urological implant
DE10137102A1 (en) * 2001-07-30 2003-02-27 Deutsches Krebsforsch Polyvalent vaccine against diseases caused by papillomaviruses, processes for their production and their use
US20030064965A1 (en) * 2001-10-02 2003-04-03 Jacob Richter Method of delivering drugs to a tissue using drug-coated medical devices
CA2457564C (en) * 2001-10-05 2009-04-07 Surmodics, Inc. Particle immobilized coatings and uses thereof
US20030100830A1 (en) * 2001-11-27 2003-05-29 Sheng-Ping Zhong Implantable or insertable medical devices visible under magnetic resonance imaging
US7488313B2 (en) * 2001-11-29 2009-02-10 Boston Scientific Scimed, Inc. Mechanical apparatus and method for dilating and delivering a therapeutic agent to a site of treatment
US20040147466A1 (en) * 2002-01-17 2004-07-29 Barman Shikha P. Nucleic acid delivery formulations
WO2003061715A1 (en) 2002-01-22 2003-07-31 Pharmacia & Upjohn Company Infection-resistant medical devices
AR038926A1 (en) * 2002-03-13 2005-02-02 Novartis Ag MATERIALS WITH MULTIPLE VESICLE LAYER CONTENT
US7519418B2 (en) * 2002-04-30 2009-04-14 Boston Scientific Scimed, Inc. Mechanical apparatus and method for dilating and delivering a therapeutic agent to a site of treatment
EP1509256B1 (en) 2002-05-24 2009-07-22 Angiotech International Ag Compositions and methods for coating medical implants
US8313760B2 (en) 2002-05-24 2012-11-20 Angiotech International Ag Compositions and methods for coating medical implants
US20050129769A1 (en) * 2002-06-03 2005-06-16 Barry Stephen E. Polymeric articles for carrying therapeutic agents
US20040034336A1 (en) * 2002-08-08 2004-02-19 Neal Scott Charged liposomes/micelles with encapsulted medical compounds
US20040260272A1 (en) * 2002-10-22 2004-12-23 Friedman Craig D. Method and system for intravesicular delivery of therapeutic agents
US7718189B2 (en) 2002-10-29 2010-05-18 Transave, Inc. Sustained release of antiinfectives
US7544369B2 (en) * 2002-10-29 2009-06-09 Transave, Inc. Sustained release of antiinfectives
US20040148016A1 (en) * 2002-11-07 2004-07-29 Klein Dean A. Biocompatible medical device coatings
US6992127B2 (en) 2002-11-25 2006-01-31 Ast Products, Inc. Polymeric coatings containing a pH buffer agent
US7597903B2 (en) * 2002-12-02 2009-10-06 Shenkar College Of Engineering And Design Method and composition for producing catheters with antibacterial property
US8048407B2 (en) * 2003-04-24 2011-11-01 Brent Vernon In situ gelling self-reactive materials for embolization
US20040254545A1 (en) * 2003-06-16 2004-12-16 Rider Dean Loller Method and apparatus for extending feeding tube longevity
JP4320572B2 (en) * 2003-07-11 2009-08-26 ソニー株式会社 Signal processing apparatus and method, recording medium, and program
EP1660153A2 (en) * 2003-09-04 2006-05-31 The United States of America as represented by the Department of Veterans Affairs Hydrogel nanocompsites for ophthalmic applications
US20050074453A1 (en) * 2003-10-02 2005-04-07 Ferree Bret A. Methods of preventing adhesions following laminectomies and other surgical procedures
ATE524203T1 (en) * 2003-11-03 2011-09-15 Medtronic Inc HYDROGEL FOR CELL-SPECIFIC INGROWTH
CA2536188A1 (en) * 2003-11-20 2005-06-09 Angiotech International Ag Electrical devices and anti-scarring agents
US20050112151A1 (en) * 2003-11-20 2005-05-26 Horng Liou L. Skin adherent hydrogels
US20050208095A1 (en) * 2003-11-20 2005-09-22 Angiotech International Ag Polymer compositions and methods for their use
EP1694333A2 (en) * 2003-11-25 2006-08-30 Deltanoid Pharmaceuticals, Inc. Methods for reducing body fat using vitamin d compounds
EP1773415A1 (en) * 2004-06-30 2007-04-18 Covalon Technologies Inc. Non-adhesive hydrogels
US7221982B2 (en) * 2004-07-12 2007-05-22 Cardiac Pacemakers, Inc. Apparatus and method of coating implantable leads
US9801982B2 (en) 2004-09-28 2017-10-31 Atrium Medical Corporation Implantable barrier device
WO2006037080A2 (en) 2004-09-28 2006-04-06 Atrium Medical Corporation Uv cured gel and method of making
US9000040B2 (en) 2004-09-28 2015-04-07 Atrium Medical Corporation Cross-linked fatty acid-based biomaterials
US8312836B2 (en) 2004-09-28 2012-11-20 Atrium Medical Corporation Method and apparatus for application of a fresh coating on a medical device
US8001922B2 (en) 2004-09-28 2011-08-23 Atrium Medical Corporation Application of a coating on a medical device
US8367099B2 (en) 2004-09-28 2013-02-05 Atrium Medical Corporation Perforated fatty acid films
US9012506B2 (en) 2004-09-28 2015-04-21 Atrium Medical Corporation Cross-linked fatty acid-based biomaterials
EP1793872B1 (en) * 2004-09-30 2016-05-11 Covalon Technologies Inc. Non-adhesive elastic gelatin matrices
US20090104254A1 (en) * 2004-12-22 2009-04-23 Rutgers, The State University Of New Jersey Controlled Release Hydrogels
US20090123512A1 (en) * 2005-01-21 2009-05-14 Ute Muh Quorum Sensing Modulators
AU2005100176A4 (en) * 2005-03-01 2005-04-07 Gym Tv Pty Ltd Garbage bin clip
US7785302B2 (en) 2005-03-04 2010-08-31 C. R. Bard, Inc. Access port identification systems and methods
US7947022B2 (en) 2005-03-04 2011-05-24 C. R. Bard, Inc. Access port identification systems and methods
US8029482B2 (en) 2005-03-04 2011-10-04 C. R. Bard, Inc. Systems and methods for radiographically identifying an access port
US9474888B2 (en) 2005-03-04 2016-10-25 C. R. Bard, Inc. Implantable access port including a sandwiched radiopaque insert
BRPI0609126A2 (en) * 2005-03-21 2010-02-23 Lifecare Innovations Pvt Ltd inter and intra multilamellar vesicular composition
EP1874393B1 (en) * 2005-04-27 2017-09-06 C.R.Bard, Inc. Infusion apparatuses
EP2939703B1 (en) 2005-04-27 2017-03-01 C. R. Bard, Inc. Infusion apparatuses and related methods
US10307581B2 (en) 2005-04-27 2019-06-04 C. R. Bard, Inc. Reinforced septum for an implantable medical device
EP1893130A4 (en) 2005-06-17 2015-08-26 Georgia Tech Res Inst Coated microstructures and method of manufacture thereof
US7919583B2 (en) * 2005-08-08 2011-04-05 Discovery Genomics, Inc. Integration-site directed vector systems
JP5393151B2 (en) * 2005-09-01 2014-01-22 メダ アーベー Liposome compositions containing antihistamines and corticosteroids and their use for the manufacture of a medicament for the treatment of rhinitis and related diseases
US9278161B2 (en) 2005-09-28 2016-03-08 Atrium Medical Corporation Tissue-separating fatty acid adhesion barrier
US9427423B2 (en) 2009-03-10 2016-08-30 Atrium Medical Corporation Fatty-acid based particles
JP2009511215A (en) 2005-10-15 2009-03-19 アトリウム メディカル コーポレーション Hydrophobic crosslinked gel for bioabsorbable drug carrier coating
CA2631872C (en) 2005-12-08 2014-04-01 Transave, Inc. Lipid-based compositions of antiinfectives for treating pulmonary infections and methods of use thereof
WO2007084418A2 (en) * 2006-01-13 2007-07-26 Surmodics, Inc. Microparticle containing matrices for drug delivery
US20070184085A1 (en) * 2006-02-03 2007-08-09 Boston Scientific Scimed, Inc. Ultrasound activated medical device
ITMI20060556A1 (en) * 2006-03-24 2007-09-25 Univ Pavia INTERACTIVE MEDICATIONS FOR THE CARE OF DERMATOLOGICAL DISEASES
DE102006015271A1 (en) * 2006-04-01 2007-10-11 Lohmann & Rauscher Gmbh & Co. Kg Biguanide-containing liposomes
EP2037977A2 (en) * 2006-06-28 2009-03-25 SurModics, Inc. Active agent eluting matrices with particulates
US9492596B2 (en) 2006-11-06 2016-11-15 Atrium Medical Corporation Barrier layer with underlying medical device and one or more reinforcing support structures
JP2010508897A (en) 2006-11-06 2010-03-25 アトリウム メディカル コーポレーション Coated surgical mesh
US9265912B2 (en) 2006-11-08 2016-02-23 C. R. Bard, Inc. Indicia informative of characteristics of insertable medical devices
US9642986B2 (en) 2006-11-08 2017-05-09 C. R. Bard, Inc. Resource information key for an insertable medical device
US8425459B2 (en) 2006-11-20 2013-04-23 Lutonix, Inc. Medical device rapid drug releasing coatings comprising a therapeutic agent and a contrast agent
US9700704B2 (en) 2006-11-20 2017-07-11 Lutonix, Inc. Drug releasing coatings for balloon catheters
US8414526B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Medical device rapid drug releasing coatings comprising oils, fatty acids, and/or lipids
US20080276935A1 (en) 2006-11-20 2008-11-13 Lixiao Wang Treatment of asthma and chronic obstructive pulmonary disease with anti-proliferate and anti-inflammatory drugs
US9737640B2 (en) 2006-11-20 2017-08-22 Lutonix, Inc. Drug releasing coatings for medical devices
US8414525B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Drug releasing coatings for medical devices
US8414909B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Drug releasing coatings for medical devices
US8998846B2 (en) 2006-11-20 2015-04-07 Lutonix, Inc. Drug releasing coatings for balloon catheters
US8414910B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Drug releasing coatings for medical devices
KR101428122B1 (en) 2006-12-15 2014-08-07 라이프본드 엘티디. Gelatin-transglutaminase hemostatic dressings and sealants
US20080181928A1 (en) * 2006-12-22 2008-07-31 Miv Therapeutics, Inc. Coatings for implantable medical devices for liposome delivery
EP1980277A1 (en) * 2007-03-17 2008-10-15 Peter Hildebrandt Gastroenterological medical product, in particular stent for the bile duct or pancreatic duct
US8093039B2 (en) * 2007-04-10 2012-01-10 The Trustees Of The Stevens Institute Of Technology Surfaces differentially adhesive to eukaryotic cells and non-eukaryotic cells
US20100196455A1 (en) 2007-05-04 2010-08-05 Transave, Inc. Compositions of Multicationic Drugs for Reducing Interactions with Polyanionic Biomolecules and Methods of Use Thereof
US9119783B2 (en) 2007-05-07 2015-09-01 Insmed Incorporated Method of treating pulmonary disorders with liposomal amikacin formulations
US9114081B2 (en) 2007-05-07 2015-08-25 Insmed Incorporated Methods of treating pulmonary disorders with liposomal amikacin formulations
DE102007039871A1 (en) * 2007-08-21 2009-02-26 Friedrich-Baur-Gmbh Soft tissue implant with antibacterial effect
WO2009029257A1 (en) * 2007-08-27 2009-03-05 Theravance, Inc. Disubstituted alkyl-8-azabicyclo [3.2.1.] octane compounds as mu opioid receptor antagonists
CN101918050A (en) * 2007-10-10 2010-12-15 Miv治疗有限公司 Lipid coatings for implantable medical devices
US9579496B2 (en) 2007-11-07 2017-02-28 C. R. Bard, Inc. Radiopaque and septum-based indicators for a multi-lumen implantable port
US9308068B2 (en) 2007-12-03 2016-04-12 Sofradim Production Implant for parastomal hernia
US8496954B2 (en) * 2008-04-18 2013-07-30 Surmodics, Inc. Coating systems for the controlled delivery of hydrophilic bioactive agents
US20090285882A1 (en) * 2008-04-22 2009-11-19 Jochen Weiss Stabilized Liposome Compositions and Related Methods of Use
EP2303026B1 (en) 2008-06-17 2020-09-09 Brigham Young University Cationic steroid antimicrobial diagnostic, detection, screening and imaging methods
EP2310459B1 (en) 2008-06-18 2014-10-22 Lifebond Ltd Improved cross-linked compositions
EP2303341A2 (en) * 2008-06-18 2011-04-06 Lifebond Ltd A method for enzymatic cross-linking of a protein
WO2009153748A2 (en) * 2008-06-18 2009-12-23 Lifebond Ltd Methods and devices for use with sealants
WO2009156866A2 (en) 2008-06-27 2009-12-30 Sofradim Production Biosynthetic implant for soft tissue repair
US20100105140A1 (en) * 2008-07-16 2010-04-29 Fahrenkrug Scott C Plaice dna transposon system
WO2010024898A2 (en) 2008-08-29 2010-03-04 Lutonix, Inc. Methods and apparatuses for coating balloon catheters
US20100070013A1 (en) * 2008-09-18 2010-03-18 Medtronic Vascular, Inc. Medical Device With Microsphere Drug Delivery System
BRPI0919890B8 (en) 2008-10-31 2019-09-24 Bard Inc C R access port to provide subcutaneous access to a patient, and force injectable access port
US11890443B2 (en) 2008-11-13 2024-02-06 C. R. Bard, Inc. Implantable medical devices including septum-based indicators
US8932271B2 (en) 2008-11-13 2015-01-13 C. R. Bard, Inc. Implantable medical devices including septum-based indicators
US20100239630A1 (en) * 2009-03-20 2010-09-23 Wilson Kurt Whitekettle Phosphonium salts delivery systems
US20100239651A1 (en) * 2009-03-20 2010-09-23 Wilson Kurt Whitekettle Nitrilopropionamide delivery systems
US20100239626A1 (en) * 2009-03-20 2010-09-23 Wilson Kurt Whitekettle Propanediol delivery systems
US20100239627A1 (en) * 2009-03-20 2010-09-23 Wilson Kurt Whitekettle Quarternary ammonium salts delivery systems
US20100239650A1 (en) * 2009-03-20 2010-09-23 Wilson Kurt Whitekettle Isothiazolin biodelivery systems
US20100249783A1 (en) * 2009-03-24 2010-09-30 Warsaw Orthopedic, Inc. Drug-eluting implant cover
US20100247600A1 (en) * 2009-03-24 2010-09-30 Warsaw Orthopedic, Inc. Therapeutic drug eluting implant cover and method of making the same
US9078712B2 (en) * 2009-04-15 2015-07-14 Warsaw Orthopedic, Inc. Preformed drug-eluting device to be affixed to an anterior spinal plate
US9414864B2 (en) 2009-04-15 2016-08-16 Warsaw Orthopedic, Inc. Anterior spinal plate with preformed drug-eluting device affixed thereto
CA2764110A1 (en) * 2009-06-02 2010-12-09 Concept Medical Inc. Rejuvenating coronary artery by improving blood flow with the help of insertion of nano-balls (encapsulated nanoparticles) containing therapeutic agents by non implantable devicefor tissues and thereby providing in tissue release to address the required cell cycle
US20110038910A1 (en) 2009-08-11 2011-02-17 Atrium Medical Corporation Anti-infective antimicrobial-containing biomaterials
FR2949688B1 (en) 2009-09-04 2012-08-24 Sofradim Production FABRIC WITH PICOTS COATED WITH A BIORESORBABLE MICROPOROUS LAYER
EP2498763A4 (en) 2009-11-09 2015-10-07 Spotlight Technology Partners Llc Polysaccharide based hydrogels
AU2010314994B2 (en) 2009-11-09 2016-10-06 Spotlight Technology Partners Llc Fragmented hydrogels
WO2011062750A1 (en) 2009-11-17 2011-05-26 C. R. Bard, Inc. Overmolded access port including anchoring and identification features
CN102711853B (en) 2009-12-22 2015-05-20 生命连结有限公司 Modification of enzymatic crosslinkers for controlling properties of crosslinked matrices
WO2011076924A1 (en) 2009-12-23 2011-06-30 Dsm Ip Assets B.V. Method to activate silicone rubber surfaces
EP2593141B1 (en) 2010-07-16 2018-07-04 Atrium Medical Corporation Composition and methods for altering the rate of hydrolysis of cured oil-based materials
WO2012016048A1 (en) 2010-07-28 2012-02-02 Life Technologies Corporation Anti- viral azide-containing compounds
US20120028335A1 (en) 2010-07-28 2012-02-02 Life Technologies Corporation Anti-viral azide-containing compounds
DK2600910T3 (en) 2010-08-05 2016-04-04 Lifebond Ltd Wound dressings and adhesives COMPREHENSIVE DRYING FORMATIONS
US8753608B2 (en) 2010-08-24 2014-06-17 Canon Kabushiki Kaisha Complex and contrast agent for photoimaging using the same
US20140086975A1 (en) 2010-10-15 2014-03-27 Rutgers, The State University Of New Jersey Hydrogel formulation for dermal and ocular delivery
USD682416S1 (en) 2010-12-30 2013-05-14 C. R. Bard, Inc. Implantable access port
USD676955S1 (en) 2010-12-30 2013-02-26 C. R. Bard, Inc. Implantable access port
FR2972626B1 (en) 2011-03-16 2014-04-11 Sofradim Production PROSTHETIC COMPRISING A THREE-DIMENSIONAL KNIT AND ADJUSTED
FR2977790B1 (en) 2011-07-13 2013-07-19 Sofradim Production PROSTHETIC FOR UMBILIC HERNIA
FR2977789B1 (en) 2011-07-13 2013-07-19 Sofradim Production PROSTHETIC FOR UMBILIC HERNIA
CA2842460C (en) 2011-07-20 2019-08-20 Brigham Young University Hydrophobic ceragenin compounds and devices incorporating same
US8932614B2 (en) 2011-08-25 2015-01-13 Paul B. Savage Incorporation of particulate ceragenins in polymers
US9603859B2 (en) 2011-09-13 2017-03-28 Brigham Young University Methods and products for increasing the rate of healing of tissue wounds
RU2652308C2 (en) 2011-09-13 2018-04-25 Брайем Янг Юниверсити Methods and products for healing tissue wounds
CA2852989C (en) 2011-09-13 2021-06-29 Brigham Young University Compositions for treating bone diseases and broken bones
US9694019B2 (en) 2011-09-13 2017-07-04 Brigham Young University Compositions and methods for treating bone diseases and broken bones
EP2760494B1 (en) 2011-09-30 2017-04-19 Sofradim Production Reversible stiffening of light weight mesh
JP6111013B2 (en) * 2011-10-30 2017-04-05 株式会社セルシード Tendon cell sheet and manufacturing method thereof
CN104379120A (en) 2011-12-21 2015-02-25 布莱阿姆青年大学 Oral care compositions
FR2985271B1 (en) 2011-12-29 2014-01-24 Sofradim Production KNITTED PICOTS
FR2985170B1 (en) 2011-12-29 2014-01-24 Sofradim Production PROSTHESIS FOR INGUINAL HERNIA
US9890361B2 (en) 2012-01-26 2018-02-13 Life Technologies Corporation Methods for increasing the infectivity of viruses utilizing alkyne-modified fatty acids
US9533063B1 (en) 2012-03-01 2017-01-03 Brigham Young University Aerosols incorporating ceragenin compounds and methods of use thereof
CA2872399C (en) 2012-05-02 2021-01-12 Brigham Young University Ceragenin particulate materials and methods for making same
US20150272880A1 (en) 2012-05-21 2015-10-01 Insmed Incorporated Systems for treating pulmonary infections
US9867880B2 (en) 2012-06-13 2018-01-16 Atrium Medical Corporation Cured oil-hydrogel biomaterial compositions for controlled drug delivery
FR2994185B1 (en) 2012-08-02 2015-07-31 Sofradim Production PROCESS FOR THE PREPARATION OF A POROUS CHITOSAN LAYER
FR2995778B1 (en) 2012-09-25 2015-06-26 Sofradim Production ABDOMINAL WALL REINFORCING PROSTHESIS AND METHOD FOR MANUFACTURING THE SAME
FR2995779B1 (en) 2012-09-25 2015-09-25 Sofradim Production PROSTHETIC COMPRISING A TREILLIS AND A MEANS OF CONSOLIDATION
FR2995788B1 (en) 2012-09-25 2014-09-26 Sofradim Production HEMOSTATIC PATCH AND PREPARATION METHOD
US10159555B2 (en) 2012-09-28 2018-12-25 Sofradim Production Packaging for a hernia repair device
US9314472B2 (en) 2012-10-17 2016-04-19 Brigham Young University Treatment and prevention of mastitis
CN104884047A (en) 2012-11-29 2015-09-02 英斯梅德股份有限公司 Stabilized vancomycin formulations
JP6294352B2 (en) 2013-01-07 2018-03-14 ブリガム・ヤング・ユニバーシティBrigham Young University Methods for reducing cell proliferation and treating certain diseases
US10568893B2 (en) 2013-03-15 2020-02-25 Brigham Young University Methods for treating inflammation, autoimmune disorders and pain
US11524015B2 (en) 2013-03-15 2022-12-13 Brigham Young University Methods for treating inflammation, autoimmune disorders and pain
KR102282183B1 (en) 2013-03-15 2021-07-26 브라이엄 영 유니버시티 Methods for treating inflammation, autoimmune disorders and pain
US9387215B2 (en) 2013-04-22 2016-07-12 Brigham Young University Animal feed including cationic cholesterol additive and related methods
FR3006581B1 (en) 2013-06-07 2016-07-22 Sofradim Production PROSTHESIS BASED ON TEXTILE FOR LAPAROSCOPIC PATHWAY
FR3006578B1 (en) 2013-06-07 2015-05-29 Sofradim Production PROSTHESIS BASED ON TEXTILE FOR LAPAROSCOPIC PATHWAY
US11690855B2 (en) 2013-10-17 2023-07-04 Brigham Young University Methods for treating lung infections and inflammation
US20150203527A1 (en) 2014-01-23 2015-07-23 Brigham Young University Cationic steroidal antimicrobials
CA2844321C (en) 2014-02-27 2021-03-16 Brigham Young University Cationic steroidal antimicrobial compounds
US9867836B2 (en) 2014-03-13 2018-01-16 Brigham Young University Lavage and/or infusion using CSA compounds for increasing fertility in a mammal
US10220045B2 (en) 2014-03-13 2019-03-05 Brigham Young University Compositions and methods for forming stabilized compositions with reduced CSA agglomeration
US9931350B2 (en) 2014-03-14 2018-04-03 Brigham Young University Anti-infective and osteogenic compositions and methods of use
US9686966B2 (en) 2014-04-30 2017-06-27 Brigham Young University Methods and apparatus for cleaning or disinfecting a water delivery system
AU2015258947B2 (en) 2014-05-15 2020-04-09 Insmed Incorporated Methods for treating pulmonary non-tuberculous mycobacterial infections
US10441595B2 (en) 2014-06-26 2019-10-15 Brigham Young University Methods for treating fungal infections
US10238665B2 (en) 2014-06-26 2019-03-26 Brigham Young University Methods for treating fungal infections
US10227376B2 (en) 2014-08-22 2019-03-12 Brigham Young University Radiolabeled cationic steroid antimicrobials and diagnostic methods
EP3000432B1 (en) 2014-09-29 2022-05-04 Sofradim Production Textile-based prosthesis for treatment of inguinal hernia
EP3000433B1 (en) 2014-09-29 2022-09-21 Sofradim Production Device for introducing a prosthesis for hernia treatment into an incision and flexible textile based prosthesis
IL234929B (en) * 2014-10-01 2021-01-31 Yeda Res & Dev Liposomes-containing antifouling compositions and uses thereof
US10155788B2 (en) 2014-10-07 2018-12-18 Brigham Young University Cationic steroidal antimicrobial prodrug compositions and uses thereof
EP3029189B1 (en) 2014-12-05 2021-08-11 Sofradim Production Prosthetic porous knit, method of making same and hernia prosthesis
US9757774B2 (en) 2015-01-15 2017-09-12 MyExposome, Inc. Passive sampling devices
EP3059255B1 (en) 2015-02-17 2020-05-13 Sofradim Production Method for preparing a chitosan-based matrix comprising a fiber reinforcement member
US10370403B2 (en) 2015-04-22 2019-08-06 Brigham Young University Methods for the synthesis of ceragenins
WO2016172553A1 (en) 2015-04-22 2016-10-27 Savage Paul B Methods for the synthesis of ceragenins
EP3085337B1 (en) 2015-04-24 2022-09-14 Sofradim Production Prosthesis for supporting a breast structure
US10126298B2 (en) 2015-05-04 2018-11-13 Arman Nabatian Hydrogels containing embedded substrates for targeted binding of molecules
JP6816121B2 (en) * 2015-05-14 2021-01-20 アソシエーション フォー ジ アドバンスメント オブ ティシュー エンジニアリング アンド セル ベイスト テクノロジーズ アンド セラピーズ(エイ4テック)− アソシアソンAssociation For The Advancement Of Tissue Engineering And Cell Based Technologies & Therapies (A4Tec) − Associacao Ureteral stents, methods and their use
US9434759B1 (en) 2015-05-18 2016-09-06 Brigham Young University Cationic steroidal antimicrobial compounds and methods of manufacturing such compounds
EP3106185B1 (en) 2015-06-19 2018-04-25 Sofradim Production Synthetic prosthesis comprising a knit and a non porous film and method for forming same
SG10201913355RA (en) 2015-09-17 2020-02-27 Histide Ag Pharmaceutical association for converting a neoplastic cell into a non-neoplastic cell and uses thereof
RU2617062C1 (en) * 2015-10-22 2017-04-19 Акционерное общество "Медсил" Plastic endoprosthesis for stenting pancreatic ducts
EP3195830B1 (en) 2016-01-25 2020-11-18 Sofradim Production Prosthesis for hernia repair
US10792477B2 (en) 2016-02-08 2020-10-06 Orbusneich Medical Pte. Ltd. Drug eluting balloon
CN108601930B (en) * 2016-02-08 2021-12-14 祥丰医疗私人有限公司 Drug eluting balloon
US10226550B2 (en) 2016-03-11 2019-03-12 Brigham Young University Cationic steroidal antimicrobial compositions for the treatment of dermal tissue
RU2624535C1 (en) * 2016-10-14 2017-07-04 Акционерное общество "Медсил" Plastic endoprosthesis for stenting pancreatic ducts
EP3312325B1 (en) 2016-10-21 2021-09-22 Sofradim Production Method for forming a mesh having a barbed suture attached thereto and the mesh thus obtained
WO2018129470A1 (en) * 2017-01-09 2018-07-12 The Board Of Trustees Of The Leland Stanford Junior University Reversing deficient hedgehog signaling restores deficient skeletal regeneration
US10959433B2 (en) 2017-03-21 2021-03-30 Brigham Young University Use of cationic steroidal antimicrobials for sporicidal activity
EP3398554A1 (en) 2017-05-02 2018-11-07 Sofradim Production Prosthesis for inguinal hernia repair
US20200276362A1 (en) * 2017-09-29 2020-09-03 Bard Shannon Limited Composition and method for controlled drug release from a tissue
JP2021519777A (en) 2018-03-30 2021-08-12 インスメッド インコーポレイテッド Continuous manufacturing method of liposome drugs
EP3653171A1 (en) 2018-11-16 2020-05-20 Sofradim Production Implants suitable for soft tissue repair

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4442133A (en) * 1982-02-22 1984-04-10 Greco Ralph S Antibiotic bonding of vascular prostheses and other implants
US4749585A (en) * 1986-04-11 1988-06-07 University Of Medicine And Dentistry Of New Jersey Antibiotic bonded prosthesis and process for producing same
US5575815A (en) * 1988-08-24 1996-11-19 Endoluminal Therapeutics, Inc. Local polymeric gel therapy
WO1991009616A1 (en) * 1989-12-22 1991-07-11 Yale University Quinolone antibiotics encapsulated in lipid vesicles
FR2668063A1 (en) * 1990-10-17 1992-04-24 Fabre Pierre Cosmetique LIPOSOMES OF THERMAL WATER STABILIZED IN A DNA GEL.
ATE148994T1 (en) * 1990-12-04 1997-03-15 Zenith Technology Corp Ltd ARTIFICIAL SKIN
CA2097163C (en) * 1992-06-01 2002-07-30 Marianna Foldvari Topical patch for liposomal drug delivery system
US5863556A (en) * 1993-08-20 1999-01-26 Euro-Celtique, S.A. Preparations for the external application of antiseptic agents and/or agents promoting the healing of wounds
US5433745A (en) * 1993-10-13 1995-07-18 Allergan, Inc. Corneal implants and methods for producing same
JPH09511666A (en) * 1994-04-08 1997-11-25 アトリックス・ラボラトリーズ・インコーポレイテッド Ancillary polymer systems for use in medical devices
US5741516A (en) * 1994-06-20 1998-04-21 Inex Pharmaceuticals Corporation Sphingosomes for enhanced drug delivery
CA2181390C (en) * 1995-07-18 2001-04-24 Pankaj Modi Phospholipid formulations

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060263323A1 (en) * 2003-03-24 2006-11-23 Becton, Dickinson And Company Invisible antimicrobial glove and hand antiseptic
US8747738B2 (en) * 2006-08-15 2014-06-10 Abbott Cardiovascular Systems Inc. Sterilization methods for medical devices
US20080044553A1 (en) * 2006-08-15 2008-02-21 Abigail Freeman Sterilization methods for medical devices
US20110209442A1 (en) * 2006-08-15 2011-09-01 Abbott Cardiovascular Systems Inc. Sterilization Methods For Medical Devices
US9682162B2 (en) 2006-08-15 2017-06-20 Abbott Cardiovascular Systems Inc. Sterilization methods for medical devices
US20120093914A1 (en) * 2008-11-24 2012-04-19 Moma Therapeutics Implantable liposome embedded matrix composition, uses thereof, and polycaprolactone particles as scaffolds for tissue regeneration
US9889232B2 (en) 2008-11-24 2018-02-13 Bonus Cellora Ltd. Implantable liposome embedded matrix composition, uses thereof, and polycaprolactone particles as scaffolds for tissue regeneration
US10314935B2 (en) 2009-01-07 2019-06-11 Entrotech Life Sciences, Inc. Chlorhexidine-containing antimicrobial laminates
US8709473B1 (en) * 2009-01-28 2014-04-29 Abbott Cardiovascular Systems Inc. Method of targeting hydrophobic drugs to vascular lesions
US20140127287A1 (en) * 2011-05-11 2014-05-08 Wisconsin Alumni Research Foundation (Warf) Liposome-encapsulated hydrogels for use in a drug delivery system
US9364588B2 (en) 2014-02-04 2016-06-14 Abbott Cardiovascular Systems Inc. Drug delivery scaffold or stent with a novolimus and lactide based coating such that novolimus has a minimum amount of bonding to the coating
US11039615B2 (en) 2014-04-18 2021-06-22 Entrotech Life Sciences, Inc. Methods of processing chlorhexidine-containing polymerizable compositions and antimicrobial articles formed thereby
EP3322365A4 (en) * 2015-05-22 2019-04-17 Orthobond, Inc. Methods, compositions and techniques for polydimethylsiloxane surface modifications

Also Published As

Publication number Publication date
US20020009485A1 (en) 2002-01-24
ATE305803T1 (en) 2005-10-15
US6475516B2 (en) 2002-11-05
AU7019898A (en) 1998-11-11
AU736584B2 (en) 2001-08-02
CA2286644C (en) 2008-10-07
WO1998046287A2 (en) 1998-10-22
JP2001523124A (en) 2001-11-20
CA2286644A1 (en) 1998-10-22
US6228393B1 (en) 2001-05-08
DE69831802T2 (en) 2006-07-06
DE69831802D1 (en) 2005-11-10
EP0984798A2 (en) 2000-03-15
EP0984798B1 (en) 2005-10-05
WO1998046287A3 (en) 1999-02-11
US6132765A (en) 2000-10-17
CA2634700A1 (en) 1998-10-22

Similar Documents

Publication Publication Date Title
US6228393B1 (en) Drug delivery via therapeutic hydrogels
DiTizio et al. A liposomal hydrogel for the prevention of bacterial adhesion to catheters
ES2258482T3 (en) ELECTROPOLIMERIZABLE MONOMERS AND POLYMERIC COATINGS OF IMPLANTABLE DEVICES.
US5798115A (en) Bioresponsive pharmacologically-active polymers and articles made therefrom
US5013306A (en) Anti-infective and antithrombogenic medical articles and method for their preparation
US7056533B2 (en) Medicament incorporation matrix
US5165952A (en) Anti-infective and antithrombogenic medical articles and method for their preparation
EP0379269B1 (en) Anti-infection and antithrombogenic medical articles and method for their preparation
US4999210A (en) Anti-infective and antithrombogenic medical articles and method for their preparation
US6261271B1 (en) Anti-infective and antithrombogenic medical articles and method for their preparation
US5821343A (en) Oxidative method for attachment of biomolecules to surfaces of medical devices
JP2003519650A (en) Polymer blends as biodegradable matrices for producing biocomposites
AU2001281304A1 (en) Medicament incorporation matrix
WO2008152115A2 (en) Drug-releasing polyelectrolyte coating, method for forming a drug-releasing polyelectrolyte coating, and implantable device
US6961610B2 (en) Branched polyethylene oxide terminated biomedical polymers and their use in biomedical devices
Ghosh et al. Recent Development in Polyurethanes for Biomedical Applications
EP3411088A1 (en) Implantable medical products, a process for the preparation thereof, and use thereof
Tizio Liposomal hydrogel surface coatings for localized delivery of therapeutic compounds

Legal Events

Date Code Title Description
STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION